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For this project, we developed reporter cell lines that express viral proteins 
with the potential to be used in cell-based screening assays to select chemical 
candidates for antiviral drugs. The viral proteins expressed in these reporter 
cell lines (Hepatitis B core and precore, Hepatitis C core (1a and 4a), and 
Rabies P (BH and SADL16)) were presented in the literature as responsible for 
interfering with the IFN signaling pathway, specifically for blocking the 
expression of its key protein STAT1.  
 We cloned the viral genes into the pdl’SurvpkIB reporter plasmid and, 
through a lentiviral delivery system, infected the Hep2Mx1TIPSE cells and 
the A549Luc cells resulting in the Hep2Mx1TIPSEHBVprecore, 
Hep2Mx1TIPSEHBVcore, Hep2Mx1TIPSEHCVcore (1a and 4a), and 
A549lucRabiesP (SADL16 and BH) reporter cell lines. 
 We assessed the obtained viral cell lines according to their ability to 
block the IFN signaling pathway by using three different assays: an 
immunoblot targeting the protein STAT1, a phenotypic assay for survival in 
the presence of puromycin (in viral Hep2Mx1TIPSE cells), and a quantitative 
measure of luciferase expression (in viral A549Luc cells). 
 Concerning the immunoblot targeting STAT1, the results showed that 
only cell lines expressing the Rabies P protein (namely the 
A549lucRabiesPSADL16 cell line) were able to decrease the level of 
expression of STAT1.  
 The phenotypic assay conducted on the Hep2Mx1TIPSE viral cell lines 
were intended to show impairment of the IFN signaling pathway through the 
down-regulation of the IFN stimulated gene Mx1.  Normal Hep2Mx1TIPSE 
cells contain a puromycin resistance gene controlled by the Mx1 promoter. 
Therefore, when puromycin is added to these cells in the presence of IFN, the 
signaling pathway is activated and Mx1 as well as the puromycin resistance 
gene are expressed resulting in cell survival. Results showed that the cell lines 
expressing the HCV core and HBV precore proteins also survived puromycin 
addition. However, the Hep2Mx1TIPSEHBVcore cells died in the presence of 
puromycin suggesting that in these cells the HBVcore protein affects Mx1 
protein expression.  
 Since it was expected that all viral cell lines would be able to down-
regulate Mx1 by impairing the IFN signaling pathway, it was assumed that 
the level of viral expression may not have been enough to be detected by this 
kind of assay and therefore a quantitative study would be crucial for the 
continuation of this project.  
 The cell lines expressing the Rabies P protein demonstrated their ability 
to block STAT1 and contained a luciferase gene under the control of an IFN 
regulated promoter. These cells were therefore considered the best candidates 
for the quantitative assay. We compared the difference between luciferase 
expression in the viral cells in the presence and absence of IFN with A549Luc 
cells (control cells) and verified that in both cases there was an increase in the 
amount of luciferase expression upon the addition of IFN, which is 
concordant with the up-regulation of the IFN signaling pathway. However, 
this increase was considerably less in cells expressing the viral protein. This 
result confirms a partial blockage of the IFN signaling pathway in these cells. 
This experiment demonstrates a new alternative step in the creation of cell 
lines that express the Rabies P protein and that can be applied to the 
manufacturing process of antiviral drugs.  However, in order to achieve the 
successful production of cell lines, it would be essential to improve viral 
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1.1. Interferon System: Induction, Signaling, and Action  
 
The importance of interferon (IFN) in antiviral defense derives from its 
ability to limit viral growth during a cell’s initial infection while 
simultaneously preventing the virus from spreading to nearby cells. The IFN 
produced by infected cells signals to neighboring cells by binding to a 
receptor in those cells. This process activates the expression of hundreds of 
genes, many of which have direct or indirect antiviral activity. In addition, the 
IFN response creates a general defense in order to allow the body enough 
time to generate an adaptive response to an invading virus. 
A great deal of progress has been made toward understanding the 
function of IFN since its discovery in 1957 by Isaacs and Lindemann (Isaacs 
and Lindemann, 1957). One experiment, for example, revealed the importance 
of IFN when mice lacking IFN-(α/β) receptors were found to be incapable of 
mounting an efficient response against viral infection (Müller et al., 1994; Van 
den Broek et al., 1995). 
 
IFN belongs to a group of proteins called cytokines produced by cells as 
part of the innate response to a viral infection. The roles of IFN are various. It 
can induce enzymes that limit viral replication by interfering with cellular 
processes and it can also induce apoptosis in infected cells or activate cells of 
the adaptive immune system (Figure 1.1). 
 
IFN can be classified according to the amino acid sequence, the mode of 
induction, the receptor usage and the biological activity. There are three types 
of interferon: Types I, II, and III. Type I is primarily composed of IFN-α and 
IFN-β, Type II of IFN-γ, and Type III of IFNλ1, IFNλ2, and IFNλ3 (Ank et al., 
2006). Although different cells can produce different subtypes of IFN, all of 
the body’s cells produce Type I IFNs. For example, plasmacytoid dendritic 
 Figure 1.1: Interferon Role in Infected Cells and Neighboring Cells  
 
This figure shows a diagram explaining the role of IFN in cells. The cells 
produce IFN as part of an immune response to a viral infection. The 
production of IFN induces an antiviral state in neighboring cells where there 
is an up-regulation of innumerous antiviral genes. These genes code for 
proteins that can limit viral replication by interfering with various cellular 
processes inducing growth arrest or even apoptosis in infected cells.  
Examples of these proteins are the OAS proteins (responsible for mRNA 
degradation), the PKR protein (responsible for translational arrest), and 


















cells (pDCs) secrete IFN-α whereas fibroblasts secrete primarily IFN-β as an 
initial response to an infection then switch to IFN-α during the amplification 
of the immune response. Type II IFN is only secreted by cells of the immune 
system—by Natural Killer (NK) cells during an innate response and by 
subsets of T-lymphocytes during an adaptive response. The newly researched 
Type III IFN shows limited tissue distribution and does not appear essential 
for host survival (Ank et al., 2006; Uze and Monneron, 2007). 
Several publications confirm that there are multiple pathways leading to 
the expression of Type I IFNs: fibroblasts, hepatocytes, and conventional 
dendritic cells (cDCs) use the “classical” pathway (Figure 1.2) while pDCs use 
Toll-like receptors (TLRs) expressed on the cell surface or in endosomes to 
sense extracellular viral material (Haller et al., 2006) (Figures 1.3 and 1.4). 
 
1.1.1. Classical Pathway for Interferon Production 
 
When a virus infects a cell it produces molecular motifs such as 
dsRNA, which have pathogenic associated molecular patterns (PAMPs). 
These PAMPs can be recognized by the cells via the intracellular RNA 
helicases MDA-5 and RIG-I. In the presence of PAMPs, the helicases become 
activated and induce a cascade that will lead to the transcription of the IFN-β 
gene. In fact, RIG-I and MDA-5 interact with their downstream partner IPS-
1/Cardif/VISA/MAVS leading to the independent activation of two 
transcription factors, IRF3 and NF-κB. Once activated, both transcription 
factors IRF3 and NF-κB together with ATF-2cjun assemble cooperatively to 
form an “enhanceosome” responsible for the activation of the transcription of 
the IFN-β gene (Kawai et al., 2005; Seth et al., 2005; Xu et al., 2005) (Figure 
1.2). 
 
MDA-5 and RIG-I 
 
The helicases MDA-5 and RIG-I serve similar functions. They both 
recognize viral dsRNA produced during viral replication. However, RIG-I has 
  
Figure 1.2: Classical Pathway for IFN-β Production and IFN Signaling 
Pathway 
 
When dsRNA invades a cell the two helicases RIG-I and MDA-5 become 
activated inducing a cascade that leads to the transcription of IFN-β. RIG-I 
and MDA-5 interact with their downstream partner IPS-
1/Cardif/VISA/MAVS leading to the independent activation of two 
transcription factors, IRF3 and NF-κB. In order to activate IRF3 the adaptor 
IPS-1/Cardif/VISA/MAVS activates the molecules TBK-1 and IKKε. The 
activation of NF-κB occurs by the engagement of the IKK(α/β) subunits of the 
IΚB kinase, which are also dependent on the same adaptor as the IRF3 
activation. PKR, when activated by dsRNA can induce a signaling cascade 
that can also activate NF-κB. Once activated, both transcription factors IRF3 
and NF-κB together with ATF-2cjun activate the transcription of IFN-β.  
The produced IFN-β is then recognized by receptors in neighboring 
cells designated IFNAR and a signaling cascade is initiated. IFNAR is 
composed of two subunits, IFNAR1 and IFNAR2. When induced by IFN 
these subunits heterodimerize and the Jak1 and the Tyk2 proteins 
transphosphorylate the resulting dimmer. Tyk2 phosphorylates a tyrosine 
residue Tyr466 on IFNAR1 allowing the SH2 domain of STAT2 to bind to 
IFNAR1 and also phosphorylates STAT2 at the Tyr690 enabling STAT1 to 
bind to the complex. The newly formed heterodimer then dissociates from the 
receptor and forms a heterotrimeric complex with a DNA binding protein of 
the IRF family. This complex, designated by ISGF-3, then translocates to the 
nucleus and binds to the IFN-stimulated response elements (ISREs) present in 
the promoters of certain IFN-stimulated genes (ISGs) initiating their 
transcription. This process leads to the transcription of several antiviral 
proteins such as Mx proteins, OAS proteins, or PKR. It also leads to an up-
regulation of the transcritption of proteins that are responsible for the process 












































been shown also to recognize ssRNA molecules that contain uncapped and 
unmodified 5’triphosphate (Hornung et al., 2006).  
The activation of each helicase is specific to the type of virus that 
infects the cell. While RIG-I plays an essential role in the production of IFNs 
when cells are infected with Paramyxoviruses, the influenza virus, or the 
Japanese encephalitis virus, MDA-5 specifically pertains to infections by 
picornaviruses (Kato et al., 2006). 
 In vitro studies revealed that both MDA-5 and RIG-I bind to 
(poly(I:C))—a synthetic analogue for dsRNA. In vivo studies conducted with 
mice demonstrated that, when subjected to (poly(I:C)), mice lacking MDA-5 
did not produce interferon while those lacking RIG-I did (Kato et al., 2006). 
 Both RIG-I and MDA-5 contain an N-terminal caspase-recruiting 
domain (CARD)-like region and a C-terminal DExD/Hbox RNA helicase 
domain. The RNA binds to the helicase domain and induces a conformational 
change that enables the CARD domain to interact with the CARD domain of 
its downstream signaling partner IPS-1/Cardif/VISA/MAVS (Kawai et al., 
2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005) (Figure 1.2). 
 
Activation of the Transcription Factors NF-kB and IRF3 
 
The downstream partner IPS-1/Cardif/VISA/MAVS—its four names 
resulting from four different studies—leads to the activation of the 
transcription factors IRF3 and NF-κB through two independent pathways 
(Kawai et al., 2005). The activation of IRF3, a member of the interferon 
regulatory factor family, involves the kinases TBK-1 and IKKε, which are 
responsible for its phosphorylation (Fitzgerald et al., 2003). The 
phosphorylated IRF3 homodimerizes and enters the nucleus where it recruits 
the transcriptional coactivators p300 and the CREB-binding protein in order 
to initiate the IFN-β mRNA synthesis (Suhara et al., 2002).  
 The activation of the other transcription factor NF-κB is induced by the 
IKB-(α/β) subunits of the multicomponent IKB kinase that are recruited by 
the adaptor IPS-1/Cardif/VISA/MAVS. NF-κB can also be activated via the 
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protein kinase PKR by dsRNA. The transcription factor is predominantly 
located in the cytoplasm, in a quiescent state, bound to its inhibitory protein 
IκB. In the presence of viral dsRNA, the PKR complex activates the IKK-
β subunit. This subunit phosphorylates the IκB that is then ubiquinated by an 
E3 ubiquitin ligase and targeted for degradation. The degradation of IκB 
results in the release of an active NF-κB protein into the nucleus where it in 
turn activates the transcription of IFN-β (Zamanian-Daryoush et al., 2000) 
(Figure 1.2). 
NF-κB can be activated in response to various stimuli such as 
pathogens, stress signals, and pro-inflammatory cytokines (TNF-α and IL-1) 
and regulates both the innate and adaptive immune responses. It also 
regulates pro-inflammatory gene expression and induces the transcription of 
pro-inflammatory cytokines, chemokines, adhesion molecules, matrix 
metalloproteiases (MMPs), cyclooxygenase 2, and nitric oxide synthase (Li et 
al., 2002). 
  
Formation of the “Enhanceosome” 
 
The two transcription factors IRF3 and NF-κB together with the ATF-
2/cjun bind to the IFN-β promoter to form a multiprotein complex known as 
the “enhanceosome”. This complex is responsible for the activation of the 
transcription of IFN-β. It is generally held that the binding of IRF3 is 
indispensable for IFN induction whereas the action of NF-κB and ATF-2/cjun 
may not be essential at all (Panne et al., 2007) (Figure 1.2). 
The initial production of IFN-β leads to the expression of the protein 
IRF7, which does not normally exist in most cells save the notable exception 
of pDCs in which it helps the expression of IFN-α noted below. In the 
“enhanceosome”, the negative-acting protein IRF2 can compete with IRF3 and 
IRF7 for limited binding sites down-regulating the transcription process 
(Harada et al., 1989). 
 
Induction of IFN−α 
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Though the induction of IFN-α genes is not greatly understood, recent 
research yields potentially useful information. The IFN-α genes show no NF-
κB sites in their promoters. Instead, they have a number of binding sites for 
IRF3 and IRF7. In fibroblasts, IFN-α production occurs only during a second 
wave of induction. The reason for this is because IRF7 (which preferentially 
stimulates the production of IFN-α) does not exist in these cells. When IFN-
β  is first produced it activates a signaling pathway that induces the 
expression of different genes including the gene that codes for IRF7 (Hata et 
al., 2001; Sato et al., 2000) 
In lymphocytes, however, viral infection activates the production of 
IFN-α without the need to pre-produce IFN-β (Hata et al., 2001). Therefore, it 
is tempting to speculate that this is correlated with the pre-existence of IRF7 
in these cells. In pCDs, there is clear evidence of constitutive IRF7 expression, 
allowing them to produce substantial quantities of IFN-α as well as IFN-β 
(Honda et al., 2005). 
 
1.1.2. Other Pathways for Interferon Production 
 
IFN can also be produced through other pathways that do not involve 
recognition of nucleic acids by the helicases MDA-5 and RIG-I.  
 
1.1.2.1. dsRNA Delivered through Endosomes 
 
 Cells can have dsRNA receptors in the endosomes. These receptors are 
activated when the cell internalizes dsRNA that is present in the extracellular 
environment or is produced by the uncoating or the degradation of entire 
viral particles. One of these receptors is called Toll-like receptor 3 (TLR3). 
TLR3 is distributed widely through tissues and is expressed in dendritic cells 
(DCs). In mDCs cells it relocalizes from the endoplasmic reticulum to the 
endosomes (Johnsen et al., 2006). In bone marrow-derived macrophages it 
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relocalizes to the lysosome (Lee at al., 2006). With regards to fibroblasts, TLR3 
relocalizes from the reticulum to the endosomes and to the cell surface 
(Matsumoto et al., 2002).  
When TLR3 detects dsRNA it dimerizes and phosphorylizes. The 
dimer then recruits PI3 kinase and an adaptor called TRIF. This adaptor is 
responsible for inducing two independent cascades that lead to the activation 
of the transcription factors IRF3 and NF-κB, which are responsible for the 
induction of the transcription of the IFN-β gene (Figure 1.3). 
The IRF3 activation occurs when TRIF recruits TRAF3. This molecule 
then binds to TANK, which, in turn, binds to TBK1 and IKKε. The last two 
proteins are then responsible for phosphorylizing IRF3 and thus activating it 
(Fitzgerald et al., 2003; Hacker et al., 2006). 
Meanwhile, TRIF also recruits TRAF6 and RIP1 (Meylan et al., 2004; 
Sato et al., 2003; reviewed in Randall et al., 2008). The recruitment of TRAF6 
leads to its ubiquitination and to RIP ubiquitination as well. The 
polyubiquitinated chains are then recognized by TAB2 and TAB3, which 
chaperone the kinase TAK1 to the complex. Then NEMO, a subunit of the IKK 
complex, recognizes RIP1 thereby recruiting the IKK complex to the 
TRIF/RIP1/TRAF6/TAK1 complex. Subsequently, TAK1 phosphorylates the 
IKK-β subunit of the IKK complex inducing a downstream phosphorylation 
and degradation of IκB and the subsequent nuclear uptake of NF-κB 
(Kanayama et al., 2004; Wang et al., 2001). 
The two transcription factors now activated and in association with the 
molecule ATF-2/cjun induce the transcription of IFN-β. 
 
1.1.2.2. ssRNA Delivered through Endosomes 
   
This pathway occurs primarily in pDCs since they are one of the few 
cell lines expressing TLR7. 
When exposed to ssRNA, pDCs dependent on TLRs for IFN induction 
may initiate strong IFN responses. ssRNA activates TLR-7 which recruits the 





Figure 1.3: dsRNA Delivered Through Endossomes 
 
This diagram represents the IFN induction pathway when dsRNA is detected 
by endosomes. In this pathway, upon stimulation by dsRNA, the molecule 
TLR3 dimerizes and phosphorylizes. It then relocates from the endoplasmic 
reticulum to endosomes (in monocy DCs) or to lysosomes (in bone marrow 
derived macrophages) where it recruits PI3 kinase and TRIF. Then two 
independent cascades, which lead to the activation of the two transcription 
factors IRF3 and NF-κB, are initiated. 
 The path that leads to the activation of IRF3 starts when TRAF3 binds to 
TANK enabling this molecule to bind to TBK-1 and IKKi/IKKε. This will 
directly activate IRF3.  
 The NF-κB activation cascade involves the recruitment of TRAF-6 and 
RIP as well as TAK1 and the molecules belonging to the IKK complex. Next, 
the IKKβ subunit of the IKK complex is phosphorylated leading to the 
phosphorylation of IκB, the NF-κB inhibitor. IκB is subsequently 
ubiquitinated and degraded releasing the active NF-κB. The two transcription 
factors IRF3 and NF-κB together with ATF-2cJun can then activate the 

























(Randall and Goodbourn, 2008) 
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IRAK-4, IRAK-1, and TRAF6 (Figure 1.4). The MyD88/IRAK-1/IRAK-
4/TRAF6 complex directly binds to IRF7 and TRAF6 utilizes its ubiquitin E3 
ligase function to polyubiquitinate IRF7. The complex is then phosphorylated 
by IRAK-1 and translocated to the nucleus where it binds to the DNA and 
stimulates IFN-β transcription. Simultaneously, NF-κB is also activated 
through a TRAF6 induced pathway. In this pathway, TRAF6 recruitment 
activates the TAK1/TAB2/TAB3 and the IKK complex leading to the release 
and destruction of IκB, resulting in the nuclear uptake of NF-κB (Kanayama et 
al., 2004; Kawai et al., 2004) (Figure 1.4). 
 
1.1.2.3. DNA Delivered through Endosomes 
 
 Some Peripheral Blood Mononuclear cells (PMBCs) exhibit a response 
to foreign DNA resulting in IFN-β production. This process is similar to the 
process described for ssRNA. The receptor, which recognizes the foreign 
unmethylated DNA, is TLR9 (Figure 1.4). 
 The pathways by which pDCs and mDCs activate IFN-β gene are 
different. pDCs use the same cascade as described above for ssRNA  
delivered by endosomes involving the adaptor MyD88 in order to activate 
IRF7. NF-κB is also activated in these cells (Honda et al., 2005). For mDCs, 
however, IRF7 is not activated and instead the molecule IRF1 is used to 
induce the transcription of the IFN-β gene (Schmitz et al., 2007). 
 
1.1.2.4. Cytoplasmic DNA 
 
 The macrophages and DCs appear capable of responding to foreign 
DNA present in the cytoplasm. Mammalian genomes are relatively G-C rich 
and therefore DNAs that have a high A-T content are easily recognized as 
non-self (Ishii et al., 2006: Stetson and Medzhitov 2006). The receptor for the 
cytoplasmic DNA has been recently identified as DA1/DLM-1/2BP-1 and it is 
distinct from TLRs and RIG-I/MDA-5. The process by which IFN-β is 
 
Figure 1.4: ssRNA and DNA Delivered Through Endossomes 
 
This diagram represents the cascade of IFN induction initiated by ssRNA in 
endossomes. When stimulated by ssRNA, the molecule TLR-7 is activated 
and recruits the adaptor MyD88, which in turn recruits a complex containing 
the kinases IRAK-4, IRAK-1, and TRAF6. The MyD88/IRAK-1/IRAK-
4/TRAF6 complex directly binds to IRF7 and TRAF6 utilizes its ubiquitin E3 
ligase function to polyubiquitinate IRF7. IRAK-1 then phosphorylates the 
complex and translocates it to the nucleus where it will bind to the DNA 
stimulating the IFN-β transcription. In parallel, the transcription factor NF-κB 
is also induced by TRAF-6. This molecule activates the IKK complex leading 
to the phosphorylation of the IKKβ subunit of the IKK complex. This results 
in phosphorylation, ubiquitination, and degradation of IκB the NF-κB 
inhibitor. Subsequently, NF-κB, IRF3, and ATF-2 c-Jun activate the 
transcription of IFN-β. In the case of DNA stimuli, instead of TLR-7, TLR-9 
recognizes the nucleic acid and the same cascades are activated leading to the 




























induced is unclear and there are questions as to whether or not NF-κB is 
involved (Ishii et al., 2006; Takaoka et al., 2007). 
 
1.1.2.5. Viral Proteins 
 
 Several viral envelopes or particles have been reported as inducers of 
IFN. The most studied systems regarding viral proteins that induce IFN are 
herpes viruses. In response to either Cytomegalovirus (CMV) or Herpes 
Simplex virus-1 (HSV-1), human fibroblasts have been shown capable of 
activating the IRF3 complex formation without the need for protein synthesis. 
It is still not clear if viral entry is required to initiate IRF3 activation (Navarro 
et al., 1998; Preston et al., 2001; Mossman et al., 2001). 
  
 
1.1.3. IFN Signaling Pathway 
 
 Once produced, IFN-β activates the Jak/STAT pathway by binding to 
the appropriate receptor on the surfaces of neighboring cells (Figure 1.2). The 
receptor complex is composed of at least two different subunits (IFNAR1 and 
IFNAR2). In the absence of stimulatory signals, IFNAR1 constitutively 
associates with the kinase Tyk2 while IFNAR2 associates with the kinases 
Jak1 and STAT2. However, when stimulation occurs, the receptor subunits 
rearrange themselves and heterodimerize. Then, Jak1 and Tyk2 
transphosphorylate. Tyk2 phosphorylates a tyrosine residue Tyr466 on 
IFNAR1 allowing the SH2 domain of STAT2 to bind to IFNAR1. Tyk2 also 
phosphorylates STAT2 at its Tyr690 enabling STAT1 to bind to the complex. 
The novel heterodimer then dissociates from the receptor and forms a 
heterotrimeric complex with IRF-9, a DNA binding protein of the IRF family. 
The new complex, called ISGF3, translocates to the nucleus and binds to the 
IFN-stimulated response elements (ISREs) present in the promoters of certain 
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IFN-stimulated genes (ISGs) initiating their transcription (reviewed in Haller 
et al., 2006) (Figure 1.2). 
 An alternate and contrasting process of signal transduction is called 
attenuation. Though little is known about this process, a number of proteins 
including IRF2 and IRF-8 have been reported to bind to ISREs and negatively 
regulate their expression. This helps to prevent IFN-response (Harada et al., 
1989; Nelson et al., 1993). 
 
1.1.4. Antiviral Proteins 
 
 There are several types of ISGs that code for antiviral proteins. Three of 
these proteins are the protein kinase R (PKR), 2'-5' oligoadenylate synthetase 




 The IFN-inducible PKR is a serine threonine kinase. PKR has two 
domains with different functions: the C-terminal domain has a catalytic 
function and contains all the conserved motifs for protein kinase activity 
whereas the N-terminal domain contains the dsRNA-binding site. PKR is 
synthesized in an inactive form and activates in response to dsRNA (Katze et 
al., 1991; Meurs et al., 1990). A stress-activated protein called PACT can also 
activate PKR (Peters et al., 2001). 
 PKR also plays a decisive role in the induction of the transcription 
factor NF-κB (see chapter 1.1.1). PKR is important in cell-regulatory processes 
such as cell growth, antiviral states, and apoptosis. In order to regulate 
apoptosis, PKR is responsible for the phosphorylation of the α subunit of the 
eukaryotic translation initiation factor eIF2 resulting in the inhibition of 
translation required for protein synthesis (Balachandran et al., 1998; Gil et al., 
1999). Another process by which PKR can regulate apoptosis involves Fas, a 
widely known cell surface receptor. The gene that codes for Fas is 
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upregulated upon PKR induction leading to the recruitment of the Fas 
associated protein named FADD. Subsequently, caspase 8 is also recruited 
and this protein is responsible for executing apoptosis in the cells (Gil et al., 
2000; Nanduri et al., 1998). 
Although the protein PKR is extremely important for antiviral 
response, studies with mice have shown that it is not sufficient to entirely 
mediate the antiviral response (Yang et al., 1995). 
 
2’-5’Oligoadenylate Synthetase System 
 
 The 2’-5’Oligoadenylate Synthetase System (OAS) consists of a group 
of enzymes that use dsRNA as a cofactor. These proteins oligomerise ATP 
through a 2’-5’ phosphodiester linkage producing 2’-5’oligonucleates that 
bind to the endoribonuclease RNase L thereby activating it. The RNase L 
protein degrades viral and cellular RNAs. This system appears to be 
important for the defense against the vaccinia virus, the reovirus, and the 




 An alternative pathway for an antiviral response involves the Mx 
proteins. The IFN-inducible Mx proteins are highly conserved large GTPases 
with homology to dynamin (reviewed in Staeheli et al., 1993). Some examples 
of Mx proteins include the Mx1 and the MxA. The Mx proteins interfere with 
virus replication by inhibiting virus polymerase activity at certain points in a 
virus lifecycle. This results in much slower virus growth (Stranden et al., 
1993). Mx 1 proteins have been shown to inhibit growth of Orthomyxoviridae 
viruses whereas MxA proteins suppress the growth of Orthomyxoviridae, 
Paramyxoviridae, Rhabdviridae, Bunyaviridae and Thogaviridae viruses (reviewed 
in Goodbourn et al., 2000). Studies show that human MxA protein recognizes 
the viral nucleoprotein of the Thogoto virus and prevents incoming viral 
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nucleaocapsids from being transported into the nucleus and impairing a viral 
response (Weber at al., 2000). 
 
 While PKR, RNase L, and Mx are the most well understood antiviral 
proteins, several others exist. This has been demonstrated experimentally 
with cells from triple knockout mice still able to exhibit a limited IFN-induced 
antiviral state (Zhou et al., 1999). These other proteins include ISG15 (Pitha-
Rowe et al., 2007), ISG54, ISG56 (Terenzi et al., 2005), PML bodies (Everett and 
Chelbi-Alix, 2007), APOBECs, TRIMs (Towers et al., 2007), and Adenosines 
Diamenases (reviewed in Toth et al., 2006). 
 
1.1.5. Virus Countermeasures to IFN Responses 
 
 There are three primary methods by which a virus counteracts cell 
response to infection: inhibiting the production of IFN, inhibiting the IFN 
signaling pathway, or inhibiting the IFN-induced anti-viral proteins. Viruses 
are also capable of circumventing the IFN response if they have a replication 
system that is insensitive to it.  However, it is not always advantageous for a 
virus to inhibit cellular gene expression and cause the destruction of the host 
cell. By doing so the virus allows itself little time to replicate. 
  
Inhibition of IFN Induction 
 
 Viruses are able to inhibit IFN production. They can operate by 
sequestering dsRNA essential for the expression of the IFN-β gene. One 
example is the NS1 protein of the Influenza virus (Garcia-Sastre et al., 1998). 
The sequestration of dsRNA minimizes its dependent activation of antiviral 
gene products and also blocks possible dsRNA-induced apoptosis. Viruses 
can also interfere with important proteins of the IFN induction pathway. For 
instance, Paramyxoviruses use their V protein in order to block MDA-5 
activity (Andrejeva et al., 2004). The transcription factor IRF3 is also a target 
for some viruses such as bovine viral diarrhea virus (BVDV), which uses its 
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Npro protein to block IRF3 targeting it for degradation (Hilton et al., 2006). 
The ML protein of the Thogoto virus can also inhibit IRF3 dimerisation and 
the recruitment of the transcriptional coactivator CBP (Hagmaier et al., 2004). 
Likewise, the human papillomavirus contains the protein E6 that binds to the 
IRF3 inhibiting its activation function (Ronco et al., 1998). However, because 
there are substitutes for the IRF3 function in the IFN pathway (such as IRF1) 
inhibition is not complete. 
The other main transcription factor, NF-κB, can also be impaired by 
viruses. In fact, the African swine fever virus encodes a homologue of IκB that 
inhibits the activity of NF-κB (Powell et al., 1996). However, it has been 
established that NF-κB also induces anti-apoptotic genes and if the virus 
blocks NF-κB such genes will not be produced. This may lead to an 
enhancement of apoptosis in the infected cell that would be detrimental to the 
virus. 
  
Inhibition of IFN Signaling 
 
The inhibition of the IFN signaling pathway may occur at various 
stages by numerous kinds of viruses. Most Paramyxoviruses inhibit STAT 
proteins by a variety of methods. Parainfluenza Type 5 virus (PIV5) employs 
the V protein to target STAT1 for degradation (Didcock et al., 1999), whereas 
Human Parainfluenza virus Type 2 (HPIV2) targets STAT2 (Young et al., 
2000). The Mumps virus uses the V protein to target both STAT1 and STAT3 
(Ulane et al., 2003). The V and the P proteins of the Nipah and Hendra viruses 
sequester STAT1 and STAT2 (Rodriguez et al., 2003). The Sendai virus also 
sequesters STATs thus increasing their turnover and altering the pattern of 
STAT1 phosphorylation (revewed in Stock et al., 2005). Despite interfering 
with STAT proteins, some other Paramyxoviruses inhibit the Jak kinase 
signaling pathway by interacting with the protein RACK1 (Kubota et al., 2002; 
Yokota et al., 2003). 
 Other viruses responsible for blocking the IFN signaling pathway 
include the Rabies virus that has the P protein (which interacts with STAT1 
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and STAT2 establishing an inactive complex) (Brzozka et al., 2006), the 
Hepatitis C virus (HCV) that has the core protein (which interacts with 
STAT1 inhibiting its phosphorylation  and its interaction with STAT2) (Lin et 
al., 2006), and the Ebola virus that has the VP24 protein (which interacts with 
karyopherin alpha 1 inhibiting the nuclear transport of STATs) (Reid et al., 
2006). In addition, the HSV virus rapidly induces the expression of SOCS3, a 
cellular inhibitor of the Jak/STAT pathways (Yokota et al., 2003). Finally, 
Dengue (Ho et al., 2005), Kunjin, and West Nile  (Liu et al., 2005) viruses 
partially block the IFN signaling pathway. 
 
Inhibition of IFN Induced Antiviral Enzymes 
 
 Several viruses (such as Pox, Herpes, Influenza, and Reoviruses) 
encode proteins that are responsible for sequestering dsRNA and therefore 
preventing the activation of IFN-induced antiviral proteins (such as PKR and 
OAS). 
 Viruses can inhibit PKR by producing small and highly structured 
RNA molecules that prevent PKR dimerisation and consequently its 
activation. One example is the VA-RNA of Adenoviruses (Clarke et al, 1995). 
Viruses can also produce proteins that directly bind to PKR inhibiting it; 
examples include NS5A of HCV or NS1 of Influenza (Lu et al., 1995). Finally 
viruses can also produce proteins that induce the expression of PKR inhibitors 
such as the p58 protein of Influenza virus (Melville et al., 1999). 
 The OAS group suffers inhibition by viruses as well. Some viral 
proteins (such as the NS1 protein of the influenza virus) bind to dsRNA that, 
in turn, binds to OAS (Min & Krug, 2006). Other viruses induce RNase L 
inhibitors causing the down-regulation of this protein. The HIV-1 virus is an 
example of this process (Martinand et al., 1999). 
HBVcore/precore proteins are responsible for blocking Mx proteins (in 
particular the MxA protein) by interacting directly with their promoters 
(Fernandez et al., 2003).  
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1.1.6. Consequences of Infection for the Host 
 
 Cells infected by viruses show damage to their IFN response. 
However, if this damage is not severe the cell may survive. Some cellular 
functions seem to be controlled by IFN even in the absence of a viral infection. 
One example is the activity of osteoclasts that are known to be involved in 
bone reabsorption and that are negatively regulated by the release of small 
amounts of IFN (Takayanagi et al., 2002; Takayanagi et al., 2005). An increase 
of osteoclast activity may cause a disease called Paget’s Bone Disease. 
Although it is not completely accepted, recent studies reveal that persistent 
infection by Paramyxoviruses causes an increase in osteoclast activity and 
therefore an increase of this disease (Bender, 2003). Oddly enough, there are 
some reported advantages for hosts due to chronic/latent viral infections. 
Mice latently infected with herpes viruses are more resistant to a bacterial 
infection than non-infected mice. Also, since IFNs induce the production of Il-
15, which is responsible for stimulating memory CTLs, the continuous 
production of IFN may assist the maintenance of immune memory (Boyman 
et al., 2007). 
 
1.1.7. IFN Response and Viral Host Range 
 
 Several viruses differ in their ability to circumvent the immune 
response according to their current host. This can be due to the fact that in 
some non-original species the viral replication cycle is slower allowing the cell 
to mount more significant antiviral responses that would impair the virus 
from blocking the IFN pathways. For instance, Myxoma virus, a rabbit-
specific pox virus, does not replicate in murine or human cells because it is 
incapable of counteracting the IFN response in these animals. 
PIV5 is non-pathogenic in Severe Combined Immunodeficiency (SCID) 
mice because it fails to block the IFN signaling pathway (its V protein does 
not target STAT1 for degradation). A single amino acid change may, however, 
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allow the V protein to target STAT1 for degradation and therefore block the 
IFN signaling pathway (Young et al., 2001). 
Some viruses are, however, perfectly capable of counteracting IFN in 
species which are not their natural host. Some examples are the Npro of 
BVDV, which blocks IFN production in human, monkey, and dog species 
(Hilton et al., 2006). Also, the V protein of the Mapuera virus is capable of 
blocking IFN signaling in horse, dog, pig, monkey, and human cells 
(Hagmaeir et al., 2007). 
It was reported (Ida-Hosonuma et al., 2005) that poliovirus can 
replicate in Human-Polivirus receptor (PVR) transgenic mice. The expression 
of PVR can be observed in both target and non-target tissue. It was revealed 
that in mice where IFN was knockout, the infection had spread to tissues in 
areas other than the nervous system such as the liver or the spleen. Therefore, 
it was implicit that in this case IFN had an important role in determining the 




1.2. Viral Proteins 
 
Several viral proteins have been reported to block the IFN action 
whether during its initial production or on the following signaling cascades. 
Some examples of those viral proteins are the core and precore proteins of the 
Hepatitis B virus (HBV), the core protein of the Hepatitis C virus (HCV), the 
V protein of Paramyxoviruses, and the P protein of the Rabies virus. 
 
1.2.1. Hepatitis B Virus 
 
 The Hepatitis B virus infects a great number of people all over the 
world. The high-risk groups are well defined: homosexuals, drug addicts, 
health workers, and children of immigrants from countries where the 
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Hepatitis B virus is endemic (Alexander, 1986). The majority of individuals 
chronically infected with HBV experience severe liver disease and risk 
developing hepatocellular carcinoma (Waris et al., 2003). Patients treated with 
IFN-α show a 40% recovery rate (Fernandez et al., 2003). 
 HBV is a small DNA virus with a circular genome of 3.2Kb. Its genes C, 
S, P, and X code for different viral proteins. The C gene codes for the core 
protein and the serum e antigen; the S gene codes for three related viral 
envelope proteins known as surface antigen; the P gene codes for the viral 
polymerase P protein; and the X gene codes for a 16.5 kDa X protein (Waris et 
al., 2003). 
 The X protein is essential for the productive infection of mammalian 
cells with HBV. It does not directly bind to DNA but instead functions via 
protein-protein interaction. The X protein has been shown to function as a 
transcriptional transactivator via different molecules such as NF-κB, 
ATF/CREB, NF-AT, AP-1, C/EBP, p53, Egr-1, and STAT3. It can also activate 
signaling pathways including the mitogen-activated protein kinase (MAPK), 
the c-jun N-terminal kinase (JNK), and the Src tyrosine kinases (Waris et al., 
2003) pathways.  
 The HBV virus produces a secreted form of the structural nucleocapsid 
core protein called precore protein. The precore protein has all the amino 
acids of the core protein plus 29 N-terminal residues (Guidotti et al., 1996). 
This precore protein was suggested to be important in the progression of 
chronic Hepatitis B when mutant strains with the same protein were reported 
to be more susceptible to treatment with IFN-α (Wang et al., 2005). 
 It has been shown that HBV defective particles are implicated in a 
deficient response to IFN-α in huh7 cells. The authors have proposed that the 
core protein performs the transcriptional inhibition of IFN-α in these cells. 
Recent studies suggest a direct interaction between the precore and the core 
proteins of the HBV virus and two regions of the MxA promoter. In this way, 
these proteins contribute to the inhibition of the action of IFN-α (Fernandez et 
al., 2003; Rosmorduc et al., 1999). There are also studies that show that HBV 
induces a significant up-regulation of PP2Ac (the catalytic subunit of PP2A). 
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PP2A is a key serine/threonine phosphatase that physically interacts with 
PRMT1 (an enzyme expressed in cells). This PRMT1 enzyme is responsible for 
the arginine methylation of many proteins including histones, RNA binding 
proteins, and STAT1. Therefore, by up-regulating PP2Ac there is an inhibition 
of PRMT1 and a subsequently reduced methylation of STAT1. Unmethylated 
STAT1 has a high affinity to PIAS1 (inhibitor of DNA binding to STAT 
dimmers), which confers STAT1 a reduced ability to stimulate IFN-α target 
genes. By up-regulating PP2Ac, the virus limits the ability of STAT1 to 
stimulate the expression of IFN-α target genes (Christen et al., 2006). 
 
1.2.2. Hepatitis C Virus 
 
 The Hepatitis C virus (HCV) is classified under its own genus 
(Hepacivirus) in the Flaviridae family. Like other members of this family (such 
as the Flavivirus and the Pestivirus) the Hepacivirus has a positive-sense single 
stranded RNA genome (Yanagi et al., 1998). This genome has 9,500 
nucleotides containing a single open reading frame (ORF) that encodes a large 
poly-protein of 3,000 amino acids. This polyprotein is processed by both host 
encoded and virus encoded proteases in order to create various mature 
polypeptides. This process yields three proteins with important structural 
functions: the core protein (C), the envelope 1 protein (E1), and the envelope 2 
protein (E2). It also yields six non-structural proteins called NS2, NS3, NS4A, 
NS4B, NS5A, and NS5B. The ORF is flanked by a 5’non-coding region (NCR) 
that acts as an internal ribosome site (IRES) and a 3’NCR that consists of 
anywhere from 27 to 66 nucleotides followed by a poly(U) tract. The ORF is 
followed by 98 highly conserved base elements thought to be required for 
replication and/or packaging (Tanaka et al., 1995). 
 The majority of HCV isolates can be classified into six groups 
designated genotypes 1 through 6. More genotypes (7, 8, 9, and most recently 
10a and 11a) have also been proposed (Tokita et al., 1995). The genotypes 1 
and 2 are distributed throughout Far East Europe, the USA, and also parts of 
Africa; genotype 3 is distributed throughout Europe, the USA, Thailand, and 
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India, and also rarely in Japan. Unlike the others, genotype 4 is specific to the 
Middle East and Central and North Africa where it is particularly prevalent in 
Egypt (Chamberlain et al., 1997). Over 80% of HCV infections lead to chronic 
hepatitis and approximately 20-30% of patients in this group develop 
cirrhosis. 
 Though HCV is a major cause of morbidity and mortality worldwide 
and there is a significant need for prevention and effective treatment, neither 
a vaccine nor an absolutely efficient treatment exists. There is, however, a 
therapy that utilizes IFN-α alone or in combination with Ribavirin 
(Chamberlain et al., 1997; de Lucas et al., 2005). Ribavirin is a pro-drug (a 
chemical precursor to the drug itself) that when activated by cellular kinases 
interferes with the viral RNA metabolism. The treatment using Interferon and  
Ribavirin appears to work in only 40-60% of infected cases. This indicates that 
HCV has a mechanism for counteracting the effect of IFN-α (de Lucas et al., 
2005). If treatment utilizes only IFN-α, the response rate drops to 20%. 
 It has been reported that the HCV proteins in cell lines and in 
transgenic animals interfere with the IFN signaling pathway (Heim et al., 
1999). This interference may be connected to the core protein. The HCV core 
protein induces a reduction in the formation of the ISGF3 complex thereby 
inhibiting the Jak/STAT pathway (de Lucas et al., 2005). Studies reveal that 
an interaction exists between the HCV core protein and the STAT1 protein. 
The N-terminal 23 amino acids of the HCV core protein interact with the SH2 
region of STAT1. STAT1 is then unable to bind to STAT2, thus impairing the 
IFN signaling pathway. Several experiments indicate that point mutations in 
other key domains of STAT1 show no signs of disrupting HCV core and 
STAT1 interaction which means that the SH2 domain is indeed the essential 
domain for HCV core and STAT1 interaction (Lin et al., 2006). 
 It has also been shown that the same protein (HCV core) interferes 
with the MxA protein expression. It has been proven that the expression of 
the HCV core protein leads to a decrease in MxA levels in a dose-dependent 
manner. This suggests that the core protein inhibits IFN-α induced 
transcription of the gene that codes for the MxA protein. Several studies (Li et 
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al, 2005; Meyland et al., 2005) have demonstrated that the HCV proteins NS3-
4a may also efficiently block the IFN production pathway. These viral 
proteins colocalize with the adaptor IPS-1/Cardif/VISA/MAVS at the 
mitochondrial membrane and cleave the adaptor at its cys508, dislocating it 





 Some viruses, members of the Paramyxoviridae family, have evolved the 
ability to antagonize IFN functions by blocking the IFN signaling pathway. 
These viruses have a linear non-segmented negative-sense RNA genome of 
15-18kb. The genome consists of six genes (N, P/V(C), M, F, G, and L) that 
encode the nucleocapsid protein, the phosphoprotein (or the V protein), the 
matrix protein, the fusion glycoprotein, the attachment glycoprotein, and the 
large protein. The phosphoprotein and the large protein form the RNA-
dependent RNA polymerase. Concerning the V protein, its C-terminus has 
seven cysteine residues and is highly conserved among Paramyxoviruses. The 
V protein has been reported to be responsible for the inhibition of the IFN 
signaling pathway in some Paramyxoviruses. This process is carried out by 
inhibiting the Jak/STAT pathway. 
 
1.2.3.1. Mumps Virus 
 
 Mumps virus (MuV) uses its V protein to degrade the STAT1 protein. 
Several studies show that the V protein also inhibits STAT1 and STAT2 
phosphorylation  (Kubota et al., 2005; Yokosawa et al., 2002). The Cys-region 
in the C-terminal region of the MuV V protein decreases STAT1 production 
and thereby contributes to the blockage of the IFN signaling pathway (Kubota 
et al., 2005). The mechanism involved in the suppression of STAT2 
phosphorylation is still unknown. However, since STAT2 associates with 
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STAT1, it must be considered that such suppression could be due to the 
decrease in STAT1 production (Yokosawa et al., 2002). 
 
1.2.3.2. Parainfluenza Type 5 Virus 
 
 The Parainfluenza Type 5 virus (PIV5) expresses the V protein. This 
protein is the 222 amino-acid product of an mRNA copy of the second open 
reading frame (V/P gene) of the viral genome. Similar to other 
Paramyxoviruses, the C-terminal domain of the V protein of PIV5 does not 
induce the degradation of STAT1 in the absence of STAT2. It appears that a 
particular interdependence exists between these two proteins for degradation 
(Yokosawa et al., 2002; Precious et al., 2005). Studies have established that the 
degradation of the STAT1 protein is mediated by ubiquitination and that the 
127 kDa protein DDB1 seems to play an important role in this process. In fact, 
the V protein does not interact directly with the target molecule STAT1 but 
instead with STAT2. STAT2 interacts with DDB1 and the created complex 
targets STAT1 for ubiquitination (Precious et al., 2005). Studies to 
determine the host range of PIV5 have shown that it does not degrade STAT1 
in murine cells and thereby does not block the signaling pathway in these 
cells. The differences between mouse and human STAT2 seem to be the 
reason for this. The expression of the human STAT2 in mice can enable the 
virus to overcome the antiviral state in a murine host (Parisien et al., 2002). 
 
 
1.2.4. Rabies Virus 
 
 Members of the Rhabdoviridae family such as the Rabies virus (Rv) are 
also capable of counteracting the IFN response. Rv encodes only five viral 
proteins (though all are essential for virus replication): the nucleoprotein N, 
the phosphoprotein P, the matrix protein M, the glycoprotein G, and a large L 
RNA-dependent RNA polymerase. It has been shown that Rabies has the 
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ability to interrupt the IFN-stimulated Jak/STAT signaling pathways using 
the P protein. The P protein binds both STAT1 and STAT2 and impairs the 
translocation of the STAT1/STAT2 dimer to the nucleus. Subsequently, there 
is an accumulation of the complex in the cytoplasm. Research has shown that 
the C-terminal 10 amino-acid residues of P are the ones responsible for 
binding this protein to the STAT proteins (Brzozka et al., 2006). 
 
1.3. IFN Sensitive Viruses and Antiviral Drugs 
 
 There are two viable approaches toward the control of viral diseases: 
prevent the infection by producing a vaccine or treat the infection using an 
antiviral drug.  
Concerning the vaccine, there are safety issues that must be analyzed 
(including the reduction of side effects to a minimum). Vaccines should also 
provide a long-term protection to the host.  
Live attenuated virus vaccines have been developed. Such vaccines are 
produced using a weakened virus strain that allows the activation of all 
components of the vaccinee immune system.  Although they are considered 
easy to administer and not very expensive, there are some disadvantages to 
this kind of vaccine. For example, they can reverse to their virulence and 
cause illness to the vaccinee. Also, attenuated viruses can be difficult to grow 
in culture because most cells will produce IFN in order to respond to an 
infection. Vero cells are a good alternative in which to grow these viruses 
because they do not produce IFN. However, only certain viruses will grow in 
them. Therefore, cells that will constitutively express viral antagonists 
without producing or responding to IFN must be engineered. 
 Another alternative to using control viruses that encode IFN 
antagonists is to develop antiviral drugs. These can impair viruses from 
blocking the IFN production and signaling pathways and result in either a 
complete host recovery or at least an improvement in the therapy. Antiviral 
drugs for acute infection must be administered early in the infection process 
or prophylactically to populations at risk. Some viruses, however, replicate 
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too quickly with moderately high mutation frequencies that may be resistant 
to antiviral drugs. Antiviral drugs also play an extremely important role in 
chronic virus diseases such as those caused by the Hepatitis B and C viruses 
(Flint et al., 2000).  
 The development of antiviral drugs has been slow. A significant reason 
for this is that compounds used to build antiviral drugs often have adverse 
effects on the host. Also, the compounds must be completely efficient in 
blocking the virus. The search for compounds that can be used in antiviral 
drugs can be done by a screening cell-based assay. Compounds are generally 
arrayed in multi-well plates and robots apply the compounds to other plastic 
dishes containing the cells expressing viral proteins. After incubation an 
output is recorded. Many companies, pharmaceutical and chemical, use 
extensive libraries of chemical compounds. Some antiviral drugs have already 
been developed: Ribavirin, Acyclovir, Ganciclovir, and Amantadine. These 
antiviral drugs must be safe and are tested for toxicity in cells and animals. 
 
 Another use for viruses with advantageous results for the host 
concerns cancer therapy. Some viruses called oncolytic viruses can be useful 
in treating cancers in which the cells are deficient to the IFN response. These 
viruses can replicate and destroy only cancer cells by lysing them and thereby 
eliminate the cells from the human body. Some examples of these viruses 
include the Newcastle disease virus (NDV) (Elankumaran et al., 2006), the 
vesicular stomatitis virus (VSV) (Wollmann et al., 2007), and mutants of the 
herpes simplex virus (HSV) (Hunter et al., 1999). 
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Aim of the Project 
 
Antiviral drugs can be used toward the purpose of eliminating viral 
infections. One starting point for the development of an antiviral drug is the 
use of a screening assay with engineered cell lines to search for chemical 
compounds that can block viral proteins and therefore qualify as potential 
candidates for an antiviral drug.  
A novel method for finding viral proteins that block the IFN signaling 
pathway and could therefore be targets for certain antiviral drugs was 
suggested by Clarke et al. in 2004. The method aimed to access the ability of a 
certain viral protein (E7 of Human Papiloma virus (HPV)) in blocking the IFN 
signaling pathway. The approach involved both a quantitative and a 
qualitative assay based on cell survival. They developed cell lines expressing 
the viral protein E7 and tested those cells in the presence of IFN. The results 
showed that the cells not expressing E7 died in the presence of a certain 
compound. In fact, in these cells the IFN signaling pathway was activated and 
through this pathway the cells upregulated a gene the product of which 
metabolized the toxic compound resulting in cell death. The cells expressing 
the viral protein however, survived, indicating impairment of the IFN 
signaling pathway (Clarke et al., 2004). 
In light of this new screening method, the aim of our project is to 
develop reporter cell lines expressing viral proteins and access those proteins 
for their ability to block the IFN signaling pathway using phenotypic cell 
assays and also quantitative assays. The viral proteins in this work are chosen 
based on their proficiency for blocking the IFN signaling pathway according 
to the literature. The proteins to be used are the Hepatitis B core and precore, 
the Hepatitis C core protein of two geotypes (1a and 4a), and the P protein of 
two strains of Rabies (SADL 16 and BH). The Hepatitis B core and precore 
and the Hepatitis C core protein are going to be expressed in the Hep2 




2. Materials and Methods 
 
2.1. DNA processing and analysis 
 
2.1.1 Polymerase chain reaction (PCR) 
 
The polymerase chain reaction (PCR) was used to amplify any DNA 
segments required for cloning these segments into vectors. The DNA 
sequences were obtained using the enzyme Taq polymerase (Promega Ltd., 
UK) or PfuI (produced in-house) according to the manufacturer’s 
recommendations on a GeneAmp PCR System 2400 (Applied Biosystems). 
The oligonucleotide primers used in PCR reactions (obtained from 
Eurogentec Ltd., UK) were designed considering the restriction enzymes sites 
(Figure 3.2). 
The PCR condition parameters were generally as follows: melting at 
95ºC for 30 seconds (sec), annealing at 55ºC for 60 sec, and strand extension at 
72ºC or 68ºC (for Taq or Pful, respectively) for 90 sec. The PCR set had a 
duration of 30 cycles.  
 
2.1.2 Agarose Gel Electrophoresis 
 
The DNA was analyzed by gel electrophoresis in horizontal mini-gels 
of 0.7-1% w/v agarose (sigma-Aldrich Co Ltd., UK) in TBE buffer (0.045M 
Tris-borate, 0.001M EDTA). Before the electrophoresis, the DNA samples 
were mixed with DNA loading buffer (0.03% bromophenol blue, 0.03% xylene 
cyanol FF, 10mM Tris-HCl (pH 7.5), and 50mM EDTA (pH 8.0)) (Promega 
Ltd., UK) in the proportion of 1/6 (vbuffer/vDNA) sample. The samples were 
run along with DNA markers (1kb) ladder (Promega Ltd., UK) at 90-100 V in 
TBE buffer supplemented with 1mg/ml ethidium bromide. The 
electrophoresed DNA was visualized through UV irradiation (Gel Doc 2000 
UV transilmuminator/photography system; Bio-Rad, UK).  The exposure of 
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the gel was kept to a minimum to prevent the formation of thymidine 
dimmers.  
 
2.1.3. Plasmid DNA purification 
 
Procedures for plasmid DNA purification follow the recommended 
protocol of the QIAprep Miniprep Kit. E.coli, harboring the desired plasmid, 
was cultured in LB (Luria-Bertani containing 10g NaCl, 10g tryptone, and 5g 
yeast extract per litre) medium at 37ºC, 200rpm overnight. The next day, 1ml 
of the culture was centrifuged at 1300rpm for 1 min. The pellet bacterial cells 
were resuspended in 250µl of Buffer P1, containing RNase A. Under the 
alkaline condition, the cell resuspension was mixed by gently inverting the 
tube 6 times with 250µl of buffer P2. This buffer is composed of NaOH/SDS. 
Leaving these lyses for more than 5 min is not recommended because long 
exposure to alkaline conditions can cause an irreversibly denatured form of 
plasmid, which is resistant to the restriction enzyme digestion; during the 
lysis reaction, vigorous treatment will shear the bacterial chromosome leading 
to the contamination of the plasmid with chromosomal DNA. Therefore, 
gently inverting the tube is sufficient. Following this reaction the lysate was 
immediately, though gently, mixed with 350µl of buffer N3 containing 
sodium acetate. The high salt and low pH value properties of this buffer lead 
to the coprecipitation of chromosomal DNA, cellular debris, and denatured 
proteins. The mixture was then centrifuged at 1300 rpm for 10 minutes and 
supernatants were applied to the QIAprep column by pipetting. The columns 
were placed in the centrifuge for 1 min at 1300 rpm. After the first 
centrifuging, columns were washed by applying 0.75ml of buffer PE and 
centrifuged and then centrifuged for another min to remove the residual 
wash buffer. The columns were then transferred to clean centrifuge tubes, 
rinsed with 30µl of buffer EB, and centrifuged for a min.  
 
2.1.4 Treatment of DNA with Enzymes 
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2.1.4.1 Restriction Enzyme Digestion of DNA 
 
Analytical Restriction Enzyme Digestion 
 
In this kind of digestion, 1-3µg of DNA were incubated at 37ºC with 2 
units of the appropriate restriction enzymes (Promega Ltd., UK, or New 
England Biolabs Ltd., US) with the corresponding reaction buffer in a total of 
10µl. They were incubated for 3hrs. 
 
Preparative Restriction Enzyme Digestion 
 
The protocol for this type of digestion is identical to the analytical 
enzyme digestion, though the total volume of DNA was of 1-10µg for a total 
reaction volume of 20µl.  
 
2.1.4.2. T4 DNA Ligase Reaction 
 
For generating proper plasmid constructions, the desired DNA 
fragments and plasmid vectors were ligated by T4 DNA ligase (200 
units/reaction) in the presence of 1x ligation buffer (50mM Tris-HCl, pH 7.5; 
1mM ATP, 25mg/ml bovine serum) in the reaction volume of 20µl at 4ºC 
overnight.  
 
2.1.4.3. Screening for Positive Colonies 
 
Following the transformation of ligation reactions (see 2.2.2) into 
competent cells and the amplification of the obtained colonies, DNA was 
purified using miniprep kits (Qiagen Ltd., UK) (see 2.1.3). The miniprep 
samples were then screened to find positive clones. 5µl of the miniprep DNA 
was incubated with 2U-appropriate restriction enzymes and the respective 
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buffer in a total of 10-20µl at the temperature of 37ºC for 3h. DNA samples 
were then analyzed by agarose gel electrophoresis. 
 
2.1.5. Preparation of Plasmid DNA 
 
For small-scale preparations, bacterial cell cultures of 2-3ml were 
grown overnight at 37ºC in a shaking incubator. DNA was extracted from 
cells using the Qiagen DNA miniprep kit (see 2.1.3) (Qiagen Ltd., UK) 
according to the manufacturer’s instructions. This extraction of DNA was 
based on the alkaline lysis of bacterial cells followed by the adsorption of 
DNA onto silica in the presence of high salt. For large-scale preparations, 
bacterial cultures of 200-250 ml were grown overnight at 37ºC in a shaking 
incubator. Similarly to small-scale preparations, DNA was extracted from 
cells and purified on silica gel membrane columns using the Qiagen DNA 
maxi-prep kit (Qiagen Ltd., UK) according to the manufacturer’s instructions. 
 
2.1.6. Plasmid DNA 
 
The vectors below were used as backbone vectors or as provided DNA 
sequences for the construction of new plasmids. 
 
—pdl HBV (provided by Dr. Alvin Patel, University of Glasgow); this 
vector was used to PCR amplify the sequences corresponding to the proteins 
core and precore of HBV. 
—pdl HCV 1a and pdl HCV 4a (provided by Prof. Richard Elliot, 
University of St Andrews); these vectors were used to PCR the sequence 
corresponding to the core protein of the HCV of both genotypes 1a and 4a. 
—pdl RabiesPSADL16 and pdl RabiesPBH (provided by Dr. Nadin 
Hagendorf, Pettenkofer Institut Genzentrum Institut F. Virologie); these 
vectors were used to PCR the sequences corresponding to the P protein of the 
Rabies virus on both strains SADL16 and BH. 
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—pdl MumpsV Enders pkIB (provided by Dr. Monica Galiano, 
University of St Andrews); this plasmid was used for a transient transfection 
in a luciferase reporter assay.  
—pdl PIV5 V pkIP (provided by Dr. Yun-Hsiang Chen, University of 
St Andrews); this vector was used for a transient transfection in a luciferase 
reporter assay. 
—pdl Surv pkIB (Figure 2.1)(provided by Dr. Yun-Hsiang Chen, 
University of St Andrews); these vectors were used as backbone vectors for 
the construction of the vectors pdl HBVcorepkIB, pdlHBVprecorepkIB, pdl 
HCVcore1apkIB, pdl HCVcore4apkIB, pdl RabiesPSADL16pkIB, and pdl 
RabiesPBHpkIB. 
 
Several lentivirus vectors were constructed for transient transfections 
and the generation of stable cell lines. 
 
—pdl HBVcorepkIB (Figure 3.3); this lentivector was generated to 
express the HBV core protein in a stable cell line using the Hep2Mx1TIPSE 
cell line. 
—pdl HBVprecore pkIB (Figure 3.4); this lentivector was generated to 
express the HBV precore protein in a stable cell line using the Hep2Mx1TIPSE 
cell line. 
—pdl HCV1apkIB and pdl HCV4apkIB (Figure 3.5); these lentivectors 
were generated to express the HCV core protein of both genotypes of HCV(1a 
and 4a) in stable cell lines using the Hep2Mx1TIPSE cell line. 
—pdl RabiesPSADL16pkIB and pdl RabiesPBHpkIB (Figure 3.6 and 
3.7); these lentivectors were generated to express the Rabies P protein of both 
strains SADL16 and BH in stable cell lines using the A549Luc cell lines. 
 
2.2. Bacterial Transformations 
 



































Figure 2.1. Schematic representation of the pdl’SurPkIB  expression vector 
(Dr. Yun-Hsiang Chen, University of St Andrews).  
 
Representation of the pdl’SurPkIB plasmid to be used as a backbone vector for 
the cloning of the viral genes. This plasmid has the epitote Pk and the reporter 
gene that confers blasticidin resistance under the control of the SFFV 
promoter. The viral genes were cloned into the survivin site using the 
restriction sites for the enzymes BamHI and MluI.  
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This procedure usually produces competent bacteria with 
transformation efficiency of about 106-107 transformed colonies per 1mg of 
supercoiled plasmid DNA. The efficiency is high enough for routine plasmid 
cloning in E.coli even though it will be affected by bacterium strains. In 
preparing competent cells, LB was inoculated with DH5α cells of overnight 
culture in a 1/100 amount.  The incubation took 2 hrs at 37ºC at 120 rpm. The 
A600nm was measured after this time and when this value was between 0.4 and 
0.6 the culture was transferred into a 50ml pre-chilled sterilized tube and kept 
on ice for 30 min in the cold room (4ºC). The cells were then centrifuged at 
2800rpm for 5 min at 4ºC and the supernatant was disposed. 2.5ml of a CaCl2 
100mmol solution and 2.5ml of a 40 mmol MgSO4 solution were added and 
the pellet was resuspended gently in that mixture and kept on ice in the cold 
room. Pre-chilled glycerol was added until a concentration of 10% and the 
mixture was aliquoted in 1.5ml tubes and quickly frozen in liquid N2. Later, it 
was stored at -70ºC. 
 
2.2.2. Transformation of Competent Bacterial Cells (E. coli) 
 
For the transformation of a cloning plasmid, 5µl of DNA ligation 
reaction solution were transferred into 100µl of freshly prepared or stored 
competent cells and mixed well by swirling gently. Then this mixture was 
treated with heat-shock for 1min at 42ºC and placed on ice for 2min. 900µl of 
LB broth were added to the 100µl and the mixture was incubated at 37ºC in a 
shaker (220rpm). 1ml of the mixture was transferred to an eppendorf and 50µl 
of the recovered culture were spread into a LB plate with ampicillin. The rest 
of the mixture in the eppendorf was centrifuged at 1300rpm for 1 min and the 
pellet was resuspended in the remains of the supernantant. The mixture was 
then spread into another LB ampicillin plate. The plates were placed in an 
incubator for 24h at 37ºC. 
 
2.3. Cells and Cell Lines 
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2.3.1. Cell Lines 
 
Cell lines of human origin were used during this project. 
 
 Basic cell lines: 
 
—HEp2; human larynx carcinoma epithelial cells provided by ECACC 
(Chen, 1988). 
 —293T; human embryo kidney cells; the 293T cell line was provided by 
Prof. Richard Iggo, University of St Andrews. 
 —A549; human alveolar basal epithelial cells. 
 
Permanent cell lines: 
 
 —HEp2Mx1TIPSE cells that express tk and puromycin resistance genes 
under the control of the murine Mx1 promoter (Figure 2.2). 
  
In addition to the cell lines mentioned above, human stable cell lines 
were generated and used: 
 
 —HEp2Mx1TIPSEHBVcore; cells that express the HBV core protein 
and the resistance genes tk and puromycin under the control of the murine 
promoter Mx1. 
 —HEp2Mx1TIPSEHBVprecore; cells that express the HBV precore 
protein and the resistance genes tk and puromycin under the control of the 
murine promoter Mx1. 
 
—HEp2Mx1TIPSEHCVcore1a and HEp2Mx1TIPSEHCVcore4a; cells 
that express the HCV core protein of two different genotypes, 1a and 4a, and 
the resistance genes tk and puromycin under the control of the murine 
promoter Mx1. 






























Figure 2.2. Schematic representation of the pdl’ Mx1TIPSE vector.  
(Rodrigues, 2008)  
  
Representation of the pdl’ Mx1TIPSE vector used to produce the 
Hep2Mx1TIPSE cell line. This plasmid contains the promoter gene that  upon 
activation controls the reporter genes TK and pac. TK is the gene that 
expresses Tymidine Kinase, which interacts with the drug Ganciclovir, and 
pac the gene that confers resistance to puromycin. 
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—A549LucRabiesPSADL16 and A549LucRabiesPBH; cells that express 
the Rabies P protein of two strains (SADL16 and BH) 
 
2.3.2. Transient Transfection in 293T Cells 
 
Adherent 293T cells were transfected with DNA 24hrs after 
trypsinisation using the FugeneTM 6 reagent. The proportion of Fugene used 
was 3/2 according to the amount of DNA transfected. Eppendorfs containing 
a mixture of DMEM, Fugene, and DNA to transfect were left to rest for 30-
45min and then applied to 6-well plates. Each well contained 2ml of DMEM 
with 10% Fetal Calf Serum. The plates were incubated at 37ºC.  
 
2.3.3. Production of Lentivirus 
 
The 293 cells were maintained in Fetal Calf Serum 10% on DMEM in 
75cm3 flasks. The plasmids were transfected into these cells according to the 
following steps:  the cells were set up one day before this experiment to be 50-
80% confluent and the volume of the serum was 5ml. On the day of the 
transfection, an eppendorf for each cell line to transfect was prepared with 
100µl of DMEM, 30µl of Fugene (FugeneTM 6 Transfection Reagent 2000), 4µl 
of the DNA to be transfected, and 3µl of each of the two vectors pCMV and 
pVSV-G. These eppendorfs were left to rest on the hood for 30-45min. The 
medium of each flask was replaced with 5ml of Fetal Bovine Calf Serum 10% 
on DMEM. After 30-45min, the content of the eppendorfs was emptied to the 
flasks, which were then incubated at 37ºC. The next day, the medium was 
replaced by a fresh 5ml of the medium.  On the third day, the medium was 
collected and 5 new milliliters of medium were added to each flask, all of 
which were then collected the following day. The medium collected was 
centrifuged for 3min at 1500rpm and filtered through a Millipore Millex GP 




2.3.4. Preparation of Stable Cell Lines by Lentivirus Infection of 
Mammalian Cells 
 
The cells were adherent in a 6-well plate with 10% Newborn Calf 
Serum solution on DMEM and were 30-50% confluent on the experiment day. 
On the day of the experiment, the medium was aspirated from the wells and 
1ml of the lentivirus and 1ml of DMEM were added to each well for both 
types of lentivirus. Then polybrene, a cationic polymer used to enhance the 
efficiency of the infection, was added in the dilution of 1ml polybrene to 
500ml of medium. The plates were then centrifuged for 30min at 1500rpm and 
incubated at 37ºC for 48 hours. Some wells, where cells were not infected with 
the lentivirus, the cells were in 1ml of DMEM and 1ml of 10% Newborn Calf 




Cells in suspension in 10ml of DMEM 10% Calf Serum were added to a 
50ml sterile tube with the dilution of 5000 cells/ml. 200µl of medium of this 
tube were then added to 9.8ml of DMEM 10% Calf Serum in a second 50ml 
tube. 6ml of the previous tube were added to 24ml of DMEM 20% Calf Serum 
in a third 50ml tube. In a fourth tube with 22.5ml of DMEM 20% Calf Serum, 
7.5ml of the third tube were added.  From this tube, 6ml were taken and 
added to a fifth 50ml tube with 24ml of DMEM 20% Calf Serum. Finally, 6ml 
of the fifth tube were added to a sixth 50ml tube with 24ml of DMEM 20% 
Calf Serum. 
 200µl of the third 50ml tube were added to each well in a 96-well plate 
and the wells were topped up with DMEM 10% Calf Serum. This procedure 
was repeated for tubes 4, 5, and 6. After 7-10 days, the medium of the plates 
was replaced with fresh medium (DMEM 10% Calf Serum). After 




2.3.6. 96-Well Plate Drug Assay 
 
Cells were set up in a 96-well plate (some infected with the virus, 
others not) in a total medium (DMEM 10% Newborn Calf Serum) volume of 
100µl. On the next day, 10µg/µl of IFN were added to alternate rows of the 
plates in a dilution of 1/1000 in DMEM containing 10% Newborn Calf Serum. 
6 hours later, puromycin and Ganciclovir were added to wells (some with and 
some without IFN) of both infected and uninfected cells in dilutions of 1/1000 
puromycin and 1/250 Ganciclovir in DMEM with 10% Newborn Calf Serum. 
The concentration of both drugs was 10µg/µl.  
 




The antibodies used in this project are listed below: 
 
 —Anti-mouse Ig Texas Red conjugated Ab (Oxford Biotechnology Ltd., 
UK). 
—Anti-mouse Ig HRP linked Ab (Amersham Bioscience, UK). 
—PIV5-Pk (mAb) (Randall et al., 1987). 




Cells adherent to coverslips on 24-well plates were cultured in DMEM 
medium containing 10% Fetal Calf Serum at 37ºC with 5% CO2. The 
coverslips were washed with washing buffer (PBS containing 1% (v/v) Fetal 
Calf Serum) twice and then fixed with the fixing solution containing 5% (v/v) 
formaldehyde and 2% (w/v) sucrose in PBS for 10min at room temperature. 
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After fixation, the cells were washed twice again and permeabilized with a 
solution that contained 0.5% (v/v) IGEPAL, 10% (w/v) sucrose, and 1% (v/v) 
azide in PBS for 5min. Because the tested proteins have the PIV5-tag on the C- 
terminal end, the cells were stained with a mAb PIV5-Pk for 30min with a 
dilution of 1/200 in PBS containing 1% (v/v) Fetal Calf Serum plus azide and 
washed twice. Then the second mAb was added (sheep anti-mouse IgG 
conjugated TXRD) with DAPI in a dilution of 1/200, the same dilution as the 
first mAb. 
The coverslips were then re-fixed to avoid dissociation of the 
antibodies and washed first in PBS and then in water. They were then 
mounted on the slides with a mounting gel called citifluor. The slides were 
examined at the microscope. 
 
2.4.3. Immunoblotting  
 
Cells were adhered to a 6-well plate and incubated at 37ºC and 5% CO2. The 
cells were washed with PBS and put on ice. The wells were aspirated and 
200µl of the disruption buffer (0.15 M NaCl, 5mM EDTA pH 8, 1% Triton 
X100, 10mM Tris HCl, pH7.4, and 5M DTT, 100mM PMSF in isopropanol, 5M 
e-aminocaproci acid all in (1/1000) dilution) were added to each well in order 
to remove the cells and collect them in eppendorfs. Then the cells were 
sonicated and the tubes were boiled at 100ºC for a few minutes. A SDS page 
gel was run for about 1 hour with 1x running buffer (5x SDS Running Buffer 
(1L) Tris 15g, Glycine 72g, SDS 5 g) at 200V. At the same time, the blotting 
pads and a nitrocellulose membrane (previously activated in Methanol) were 
soaked with transfer buffer (1x Running Buffer in 205 ml methanol). The 
proteins were then transferred to the membrane by electro blotting with a 
charge of 28V for 1h30m. The nitrocellulose membrane was soaked in a 5% 
milk solution for 1h. The primary antibody was added to the membrane in a 
5% milk solution for 1 hour with a dilution of 1/2000 (v/v). Then the 
membrane was washed for 1 hour, changing medium (PBS tween) every 15 
minutes. After washing with PBS Tween, the secondary antibody was added 
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to the membrane in a dilution of 1/2000 in a 5% milk solution for another 
hour. The membrane was washed again for 1 hour. Antibody binding was 
detected by the enhanced chemiluminescence’s assay (ECL). A mixture of 
ECL 1 and ECL 2 in the ratio of 1:1 was added to the membrane and the latter 
was incubated for 5min. The membrane was then exposed to an auto-
radiographic film.  
 
2.4.4. Luciferase Reporter Assay 
 
Cell monolayers were incubated in 6-well plates at 37ºC, 5% CO2, and 
50% confluent. They were transiently transfected with both the IRES-
luciferase plasmid and the vector coding for each viral protein. 48 hours after 
transfection, IFN was added to some of the cells and then 6 hours later the 
cells were harvested and lysed. For that purpose, 200µl of Luciferase buffer A 
(5ml of Luciferase Master buffer (50mM Tris-phosphate pH7.8, 2mM DTT, 
2mM EDTA, 2% TritonX100, and16mM MgCl2) and 5ml water) were added 
for 2 min. Then 200µl of Luciferase buffer B (5ml of Luciferase Master buffer, 
3ml of Glycerol, 80µl of 100mM ATP, and 2ml of 10% BSA) were added to the 
cells. 300µl of this mixture were then transferred to a luminometer cuvette 
and 50µl of Luciferin were added. The samples were then read for the amount 
of luciferase.  
 
2.4.5. β-Galactosidase Assays 
 
900µl of buffer A–β-Mercaptoethanol mixture (100mM NaH2PO4; 10mM KCl; 
1mM MgSO4; 50mM β-Mercaptoethanol) were added to the cell lysates (from 
the lucifearse assay) in  microcentrifuge tubes and the tubes were incubated in 
a 37°C water bath for 5 minutes. 200µl of o-Nitrophenyl-β-D-
Galactopyranoside (ONPG) substrate in the concentration of 4mg/ml were 
added to 100 mM NaH2PO4 buffer (pH 7.5) resulting in a 1xONPG solution. 
This mixture was added to the tubes and the latter were vortexed for 5 
seconds. The time of ONPG addition was recorded and the reaction was 
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incubated for 30 minutes or more in a 37°C water bath until the sample 
turned bright yellow.  
 The reaction was stopped by adding 500µl of stop solution (1M Na2CO3). 
 The OD420nm was measured and the specific activity was determined. 
(OD420/0.0045 = nmoles formed per milliliter; nmoles/ml × total assay 




Part I - Generation of the Reporter Cell Lines Expressing a Viral 
Protein Responsible for Blocking the IFN Signaling Pathway in 
Hep2Mx1TIPSE Cells  
 
Hep2Mx1TIPSE cell line  
 
The Hep2 (human epithelial cells established from a laryngeal 
carcinoma) cell line available in our lab had been engineered by infection 
using a lentiviral based system transferring the genes in the vector pdl 
Mx1TIPSE (Figure 2.2). This vector contains the selection marker genes 
thymidine kinase (TK) and puromycin resistance (pac) under the control of an 
IFN-inducible promoter called the Mx1 promoter. Whenever these cells are 
treated with IFN(α/β) the expression of hundreds of genes is up-regulated as 
a result of the antiviral state the cells enter. One of these genes codes for the 
protein Mx1. Therefore, if IFN is present, the Mx1 promoter is activated and 
the cells will express the genes TK and pac. The TK gene works as a selective 
marker due to its interaction with the antiviral drug ganciclovir (GCV) 
resulting in life or death for the cells. The reason for this is that ganciclovir 
can work like a substrate for the enzyme TK and although GCV by itself is not 
toxic for the cells, when phosphorylated by TK it becomes toxic and once 
incorporated in the DNA it can cause cell death. Therefore, in the presence of 
GCV, the expression of TK results in cell death. Puromycin is an antibiotic 
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commonly used for selection in mammalian cells and it interferes with 
protein synthesis leading to the death of the cells.  
The engineered Hep2Mx1TIPSE cells were tested in the presence of 
IFN for their markers. When the cells were subjected to the drugs, they 
responded as expected (Figure 3.1). The cells to which IFN was added 
survived in the presence of puromycin (the pac gene was active) and died in 
the presence of ganciclovir (TK was active). The Hep2Mx1TIPSE cells are easy 
to grow and maintain in cell culture and are able to be passaged indefinitely. 
They can be considered good candidates for expressing IFN antagonists. 
 
Engineering Hep2Mx1TIPSE reporter cell lines expressing viral proteins 
 
The process to engineer the Hep2Mx1TIPSE reporter cells lines 
expressing certain viral proteins was initiated with the cloning of the viral 
genes into the reporter plasmid pdl’SurPkIB. 
The viral DNA was obtained from different labs (see 2.1.6.) and 
primers were designed (Figure 3.2) with consideration for the genetic 
sequences of the viral genes and the restriction enzymes present in the vector 
pdl’SurPkIB where the genes were to be cloned. These enzymes are SwaI or 
BamHI (for forward primers) and MluI (for reverse primers) (Figure 3.2.).  
A PCR was then performed in order to amplify the DNA coding for 
each viral protein to be cloned in the vector. 
Following the PCR, the PCR products were digested with the 
appropriate restriction enzymes and cloned into the same sites present in the 
pdl’SurPkIB vector thus generating the different plasmids (Figures 3.3-3.5). 
The vector pdl’SurPKIB was chosen for this cloning because it contains 
a blasticidin resistance gene under the control of the SFFV (Spleen Focus- 
forming virus) promoter. This allowed us to select the cells that contained the 
plasmid of interest by adding blasticidin. The viral genes were cloned 
upstream of a gene which codes for a 14 amino acid sequence derived from 
the P and V proteins of PIV5 designated by Pk epitote. The Pk protein worked 
as a tag to the viral protein and since we had an antibody targeting Pk we 
Figure 3.1. Response of Hep2Mx1TIPSE cells to puromycin and Ganciclovir 
after IFN treatment 
 
Hep2Mx1TIPSE cells were set up in 96-well microtitre plates. IFN was added 
to every other row twenty-four hours after the cells were set up.  Puromycin and 
ganciclovir were then added to the cells at a concentration of 10µg/µl eight hours 
after IFN had been added. Four days later the cells were fixed using a solution with 
PBS 5% formaldehyde and 2% sucrose and stained with crystal violet. 
The live cells were stained in violet whereas the dead ones were washed off. 
From Figure 3.1 we observe that, as expected, cells to which IFN was added survived 



































The primers were designed using the program DNA Strider while 
considering the restriction enzymes necessary to cut the PCR fragments in 
order to insert them into the plasmid pdl’ SurPkIB. The restriction enzyme 
used for designing the reverse primers was MluI and the enzymes used for 
designing the forward primers were BamHI or SwaI. 
  
 
Primers Restriction enzymes  Primer sequences 
HBV precore fwd  BamHI 5’ agc tag gga tcc atg caa ctt ttt cac ctc tgc 3’ 
HBV core fwd BamHI 5’ cat ccg gga tcc atg gac att gac cct tat aaa 3’ 
HBV rev (core 
and precore) MluI 5’ act gca acg cgt aca ttg aga ttc ccg aga ttg 3’ 
HCV 1a rev MluI 5’ tag ccg acg cgt ggc tga agc ggg cac agt cag 3’ 
HCV 4arev MluI 5’ cga tcg acg cgt ggc cga agc ggg gac agt cag 3’ 
HCVfwd (1a and 
4a) BamHI 5’ ccg cgc gga tcc atg agc acg aat cct aaa cct 3’ 
Rabies P fwd 
(SADL16 and 
BH) 
SwaI 5’ cgc att taa ata tga gca aga tct ttgtc 3’ 
Rabies P 
SADL16 rev MluI 3’ cgc acg cgt gca aga tgt ata gcgattt 5’ 



































Figure 3.3.  Schematic representation of the pdl’ HBVcorePkIB vector.   
 
Representation of the pdl’ HBVcorePkIB plasmid to be tranfected into 293T 
cells along with pCMV and pVSV-G in order to produce lentiviral particles to 
infect the Hep2Mx1TIPSE cells. In this representation, the locations are shown 
for the HBVcore promoter gene cloned right before the epítote Pk and the 
blasticidin gene which are under its control. The cloning site for HBVcore is 
between the enzymes BamHI and MluI. 





































Figure 3.4.  Schematic representation of the pdl’ HBVprecorePkIB vector.   
 
Representation of the pdl’ HBVprecorePkIB plasmid to be tranfected into 293T 
cells along with pCMV and pVSV-G in order to produce lentiviral particles to 
infect the Hep2Mx1TIPSE cells. In this representation, the locations are shown 
for the HBVprecore promoter gene cloned right before the epítote Pk and the 
blasticidin gene, which are under its control. The cloning site for HBVprecore 






































Figure 3.5. Schematic representation of the pdl’ HCVcorePkIB vector (1a 
and 4a).   
 
Representation of the pdl’ HCVcorePkIB plasmid to be tranfected into 293T 
cells along with pCMV and pVSV-G in order to produce lentiviral particles to 
infect the Hep2Mx1TIPSE cells. In this representation, the locations are shown 
for the HCVcore promoter gene cloned right before the epítote Pk and the 
blasticidin gene, which are under its control. The cloning site for HCVcore is 
between the enzymes BamHI and MluI. 
 
 





































Figure 3.6. Schematic representation of the pdl’ RabiesPSADL16PkIB 
vector.   
 
Representation of the pdl’ RabiesPSADL16PkIB plasmid to be tranfected into 
293T cells along with pCMV and pVSV-G in order to produce lentiviral 
particles to infect A549Luc cells. In this representation, the locations are shown 
for the RabiesPSADL16 promoter gene cloned right before the epítote Pk and 
the blasticidin gene, which are under the control of this promoter. The cloning 
site for RabiesPSADL16 is between the enzymes SwaI and MluI. 
   Rabies P SADL16  


































Figure 3.7 Schematic representation of the pdl’ RabiesPBHPkIB vector.   
 
Representation of the pdl’ RabiesPBHPkIB plasmid to be transfected into 293T 
cells along with pCMV and pVSV-G in order to produce lentiviral particles to 
infect A549Luc cells. In this representation, the locations are shown for the 
RabiesPBH promoter gene cloned right before the epítote Pk and the 
blasticidin gene, which are under the control of this promoter. The cloning site 







    RabiesP BH  
Pdl’ Rabies P BH PkIB 
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conducted several immunoblotting and immunofluorescence assays for the 
viral proteins of interest. 
The cloned vectors expressing the viral proteins pdl’HBVcorePKIB, 
pdl’HBVprecorePKIB, and pdl’HCVcorePKIB (1a and 4a) (Figures 3.3-3.5) 
were submitted for DNA sequencing to confirm a successful cloning (data not 
shown).   
 
Lentiviral Infection of Hep2Mx1TIPSE Cells and Viral Expression 
 
A lentivirus-based vector system was used to produce the reporter cell 
lines in the Hep2Mx1TIPSE cells. Lentiviruses, such as HIV, are retroviruses 
capable of infecting both dividing and non-dividing cells (Amado & Chen, 
1999). 
In this experiment, lentiviral particles were produced in the 293T 
(Human embryonic kidney) producer cell line and released in the medium 
where they were later harvested and used to infect the Hep2Mx1TIPSE cell 
line.  
The production of the lentiviral particles started with the transfection 
of the 293T cells by three different plasmids. The first plasmid, our construct 
(Figures 3.3-3.5), was engineered to contain the sequences that code for the 
viral proteins of interest to our project and that we aimed to transfer into the 
Hep2Mx1TIPSE cells. The second plasmid, pCMV (also referred to as 
packaging plasmid), contained the structural proteins (except envelope 
protein (env)) and enzymes that were crucial for the generation of the 
lentiviral particles. The third plasmid, pVSV-G, contained a sequence for the 
Glycoprotein of vesicular stomatitis virus (VSV-G). This protein acts as the 
env protein being responsible for mediating the entry of the lentiviral 
particles in the Hep2Mx1TIPSE cells (Kahl et al., 2004; Yang et al., 2006). Once 
inside the 293T cells, the DNA was transcribed into RNA and the particles 
were formed and released in the medium. The medium of the 293T cells was 
after collected and used for the infection of the Hep2Mx1TIPSE cells. This 
process was initiated when the lentiviral particles entered the Hep2Mx1TIPSE 
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cells (due to the env protein) and their RNA was reversely transcribed into 
DNA by a reverse transcriptase enzyme. This DNA, along with other 
components of the viral particle (protein Vpr and matrix and enzyme 
integrase), formed a pre-integration complex. The complex then entered the 
nucleus of the Hep2Mx1TIPSE cells and the DNA was inserted into the cell’s 
genome by the enzyme integrase (Amado and Chen, 1999). 
Using the lentivirus vector based system involved some precautionary 
measures. The major concern was that the lentiviruses could self-replicate by 
recombination; the lentiviral particles could infect humans, self-replicate and 
behave like HIV (Amado and Chen, 1999). To avoid this problem the 
packaging plasmid did not contain some HIV genes that would be essential 
for self-replication. 
Two days after infection blasticidin was added to the cells and three 
days after (the period of time necessary for blasticidin action) the new cell 
lines were assayed for viral expression. The viral expression was analyzed in 
HBVcore/precore Hep2Mx1TIPSE cells by immunofluorescence using the 
anti-pk-tag antibody. The cells were set up as monolayers and stained with 
the primary antibody anti-pk-tag and the secondary anti-mouse FITC-
conjugated antibody TX red. The use of these antibodies allowed us to see the 
cells that are expressing the viral protein colored red. The cells were also 
stained with DAPI to facilitate the observation of cell nucleus. The cell lines 
expressing HBV precore and core proteins exhibited a good expression of the 
viral proteins in question (Figure 3.9).  
An immunoblot to determine the expression of the HCV core in both 
HCV genotypes (1a and 4a) was successfully conducted. The molecular 
weight of this protein is approximately 21kDa (Figure 3.8). 
 
Blocking of the IFN Signaling Pathway 
 
To determine exactly if the viral proteins were blocking the IFN 
signaling pathway, two separate assays were performed. The first consisted of 
an immunoblot targeting the protein STAT1. In this assay, we intended to 
 
Figure 3.8: Immunoblotting analysis targeting for the HCVcore protein 
using anti Pk-tag antibody 
 
In order to check if the Hep2Mx1TIPSE cell lines expressed the viral protein 
HCVcore the cells were set up in a 6-well plate and an immunoblot was 
conducted using the anti-pktag antibody. 
In this figure the band of 21 kDa represents the HCVcore protein. The band 
was present for both genotypes of HCV (1a and 4a), although the expression 
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 Figure 3.9: Immunofluorescence analysis revealing the expression of the 
proteins precore and core of HBV in the Hep2Mx1TIPSE cells 
 
The Hep2Mx1TIPSE cells were infected with lentivirus containing the 
viral RNA in order to engineer cell lines expressing the HBV core and precore 
proteins. To ensure that the cell lines were in fact expressing the viral proteins 
we performed an immunofluorescence analysis using the anti Pk-tag 
antibody and human TXRD as a secondary antibody. From these figures we 
can observe that there is a good expression of these proteins in the 
Hep2Mx1TIPSE cells. DAPI staining was also performed in order to help 









observe any alteration in the amount of expression of this protein by 
comparing the intensity of the band representing STAT1 in the presence of 
IFN in the Hep2Mx1TIPSE cells with the band in the cells expressing a viral 
protein.  
It is known that when IFN is produced in cells (such as 
Hep2Mx1TIPSE) as the result of a viral infection or due to any other stimuli 
the IFN signaling pathway is activated and STAT1 is phosphorylated forming 
a heterodimer with STAT2. This heterodimer then translocates to the nucleus 
of the cell up-regulating different ISGs (including the gene that codes for the 
same protein STAT1) that will act as an antiviral response. Therefore, in the 
presence of IFN the amount of this protein in the cell is greater than in the 
absence of it and so we should expect the band corresponding to STAT 1 to be 
more intense in the presence of IFN. In fact, after setting up the 
Hep2MX1TIPSE cells in monolayers in six well plates and performing an 
immunoblot analysis targeting STAT1, we noticed a band around 90kDa 
corresponding to the molecular weight of the STAT1 protein. This band was 
more intense when IFN was present (Figure 3.11). In the same immunoblot 
analysis we observed that the cells expressing HCV core protein (both HCV 
genotypes 1a and 4a) (Figure 3.11) show the same result as the normal 
Hep2Mx1TIPSE cells. This result was not expected since in the cells 
expressing the HCV core the latter should reduce the quantity of 
phosphorylated STAT1. By binding to STAT1, the viral protein would avoid 
the formation of the STAT1/STAT2 heterodimer. In this manner, the ISGs 
would not become activated and the protein STAT1 would not be up-
regulated. Thus, we would not see an increase in the expression of the band 
corresponding to the molecular weight of STAT1 in the 
Hep2Mx1TIPSEHCVcore cells upon IFN addition. The above result seems to 
suggest that the HCV core protein is not blocking the up-regulation of STAT1 
contradicting what was expected (Basu et al., 2001). 
However, the protein HCV core might be able to block the interferon 
signaling pathway by affecting other key components of this pathway. For 
instance, it was reported that the HCV core protein was able to induce a 
 Figure 3.10: Immunoblotting analysis targeting the STAT1 protein 
indicating that the HBVcore and precore proteins were not blocking STAT1 
activity.  
 
The Hep2Mx1TIPSEHBVcore cells and the Hep2Mx1TIPSEHBVprecore cells 
were analyzed in an immunoblot targeting the protein STAT1. As observed 
when IFN is added to the Hep2Mx1TIPSE cells, there is an increase in the 
intensity of the band corresponding to the protein STAT1 (90kDa). This result 
is the same in the cells expressing the viral proteins HBV core and precore 
and therefore we can suggest that the viral proteins are not blocking the 
expression of STAT1. 
  
  
        





  HBVcore 
STAT1 
(90kDa) 
   -   +                                           -   +            -   + 
IFN IFN IFN 
  
Figure 3.11: Immunoblotting analysis targeting STAT1 protein indicating 
that the HCVcore protein was not blocking STAT1.  
 
The Hep2Mx1TIPSEHCVcore cells were analyzed in an immunoblot 
targeting the protein STAT1. As observed when IFN is added to the 
Hep2Mx1TIPSE cells, there is an increase of the band corresponding to STAT1 
(90kDa). The result is the same in the cells expressing the viral protein 
HCVcore and therefore we can suggest that the core protein is not blocking 
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decrease in the binding of the ISGF3 complex to the ISRE domain by means 
other than inhibiting the transcription of STAT1 (de Lucas, 2005). 
Also, the same protein, HCV core, has been shown to be capable of 
inhibiting the expression of the antiviral IFN-sensitive MxA gene and down-
regulating the expression of PKR and 2’-5’ OAS proteins (de Lucas, 2005). 
Contrastingly, previous studies (Dansako et al., 2003) have shown that 
the HCV core protein activates the 2’-5’ OAS gene. However, the activation of 
this gene appeared to involve a separate mechanism from the activation of the 
signaling pathway. There was no enhancing in the expression of the 
transcription factors STAT1 and STAT2 or the kinases JAK1 and Tyk2 by the 
core protein.   
The results for the Hep2Mx1TIPSEHBVprecore cells and the 
Hep2Mx1TIPSEHBVcore cells (Figure 3.10) were the same as for the 
Hep2Mx1TIPSEHCVcore cells: in none had the viral proteins appeared to be 
blocking the IFN signaling pathway by interfering with STAT1 production 
or/and phosphorylation.  
The Hepatitis B core and precore proteins may also be able to block the 
IFN signaling pathway by affecting other components of this pathway. This is 
strongly supported by the results in Figure 3.12.  This figure shows the results 
of an assay performed to the cells aimed to determine if the core protein of 
Hepatitis C and B and also the precore protein of Hepatitis B were involved in 
inhibiting the expression of the protein Mx1.  
This experiment involved a vital test in the presence of the antibiotic 
puromycin (Figure 3.12). The cells were set-up in 96-well plates and after IFN 
treatment puromycin was added to them. From Figure 3.1 we can observe 
that the Hep2Mx1TIPSE cells survived the puromycin addition when IFN was 
present. This happened because in the presence of IFN the IFN signaling 
pathway is activated and, as mentioned above, different Interferon stimulated 
response elements (ISREs) are also activated starting the production and up-
regulation of thousands of antiviral genes such as the one coding for the Mx1 
protein. Therefore, the Mx1 promoter, present in the Hep2Mx1TIPSE cells, is 
activated and the gene pac, which is under its control, is also activated 
 Figure 3.12: Response of Hep2Mx1TIPSE (HBVprecore, HBVcore and 
HCVcore) cells to puromycin addition while IFN treatment. 
 
The Hep2Mx1TIPSEHBVprecore (a) cells, the Hep2Mx1TIPSEHBVcore 
(b) cells, and the Hep2Mx1TIPSEHCVcore 1a (results are the same for 4a; data 
not shown) (c) cells were set up in 96-well microtitre plates. Puromycin in the 
concentration of 10µg/µl was added to the wells and the plates were fixed 
after two days. In the figure 3.12 we can observe that the cells expressing 
HBVprecore and HCVcore 1a to which we added puromycin and IFN 
survived. The cells to which IFN was not added died after two days in the 
presence of puromycin. These results are the same for the Hep2Mx1TIPSE 
cells (Figure 3.1). In all these cells the Mx1 protein is being activated as a 
result of the IFN signaling pathway. The above result therefore suggests that 
the viral proteins HBVprecore and HCVcore are not interfering with the IFN 
signaling pathway. The HBVcore infected cells (b), however, did not survive 
puromycin addition in the presence of IFN, indicating impairment on the IFN 
signaling pathway. 
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enabling the cells to resist to puromycin. In Summary, in the presence of IFN, 
the Mx1 promoter is activated leading to the activation of the puromycin 
resistance gene and the cells live (Figure 3.1). By observation of Figure 3.12c, 
we notice that the cells expressing the viral protein HCV core present the 
same result as the Hep2Mx1TIPSE cells, which leads us to conclude that in 
these cells the IFN signaling pathway is not being blocked by the viral 
proteins. However, Figure 3.12b shows us that the cells expressing the HBV 
core protein are unable to survive puromycin addition. In these cells the viral 
protein is therefore clearly affecting the transcription of Mx1 leading us to 
believe that it interferes with the IFN signaling pathway. For the cells 
expressing the HBV precore protein however, the results were the same as for 
normal Hep2Mx1TIPSE cells. 
 
Part II- Generating A549lucRabies P Cell Lines 
 
The above results and the recent publications led us to speculate 
whether the viral proteins in question really did not block STAT1 induction or 
interfere in other ways with the IFN signaling pathway, or instead the 
expression of those proteins in the cell lines engineered was not sufficient to 
allow us to have enough viral protein to observe a significant blockage of the 
IFN signaling pathway.  
With that in mind, we thought about developing a different cell line 
that instead of giving us a subjective qualitative result would give us a 
quantitative analysis of how much the viral proteins interfere with the IFN 
signaling pathway. Therefore, we chose to engineer a reporter cell line using 
the pre-existing A549Luc (human alveolar basal epithelial), cell line available 
in our lab. This cell line contains a gene that expresses luciferase. The 
luciferase reporter gene in A549Luc cells is under the control of an interferon 
stimulated promoter gene and expresses the Luciferase protein. This protein 
is able to produce bioluminescence when exposed to the right substrate. It 
catalyses the oxidation of the supplemented luciferin pigment (substrate) in a 
two-step reaction to yield oxyluciferin. The energy supplied to the reaction in 
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the form of ATP is converted to light. The emitted protons can be detected 
with a light sensitive apparatus such as a luminometer.  
However, before attempting to develop permanent cell lines 
expressing a viral protein in A549Luc cells, we performed a transient 
transfection in 293T cells followed by a luciferase reporter assay. 
In this assay, 293T cells were transiently transfected with a luciferase 
reporter vector containing an interferon stimulated response element (ISRE) 
encoding sequence promoter. They were also co-transfected with a vector 
with the viral gene of interest. The chosen viral protein was the Rabies P 
protein, which had also been reported to block the IFN signaling pathway 
(Brzozka et al., 2006). The gene for the P protein, obtained from Conzelmann 
lab in Germany, had been cloned into the pdl’SurPkIB plasmid (Figure 3.6-
3.7). We used two different strains of the Rabies virus: SADL16 and BH. The 
strains vary in their ability to block the IFN pathways. While SADL16 P is a 
mutant only able to inhibit the STAT1 protein, the P protein from the BH 
strain is able to block the TBK protein as well. 
For this transient transfection we also used a negative control (293T 
cells not transfected with any vector containing a viral gene) and two positive 
controls (293T cells co-transfected with plasmids containing the gene PIV5 V 
and the gene Mumps Enders V). It has been proven that both the viral 
proteins PIV5 V and Mumps Enders V are responsible for the blocking IFN 
signaling pathway (Precious et al., 2005; Kubota et al., 2005; Yokosawa et al., 
2002).  
We measured the luciferase expression therefore measuring the 
activity of the ISRE promoter in the presence and absence of IFN in 293T cells 
transfected with viral genes and 293T cells not transfected with the viral 
genes. We then observed the difference between the values of luciferase when 
IFN was present and when it was absent and compared these values in the 
cells lines transfected with the viral genes and the ones that weren’t. In short, 
we wanted to see if the activity of the ISRE promoter was being affected by 
the expression of the viral proteins. If that were the case, then it would mean 
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that the viral proteins would be blocking the IFN signaling pathway 
somehow, causing the down-regulation of the ISRE.  
The results for luciferase activity are expressed in Figure 3.13. From 
this figure, we observe that when IFN is added to the 293T cells there is a 
considerable increase in luciferase expression compared to the cells that were 
not treated with IFN. This indicates that the ISRE is being up-regulated in the 
presence of IFN by activation of the IFN signaling pathway. However, in the 
cells transiently transfected with vectors containing the genes that code for 
the viral proteins Mumps Enders V, PIV5 V, and Rabies P BH or Rabies P 
SADL16 the increase of luciferase expression is not as significant. This 
indicates that the activity of the ISRE promoter is not as high in cells 
transfected with viral genes, which suggests a partial blockage of the IFN 
signaling pathway.  
  The values for standard error were calculated using n=3 (n=number of 
assays performed). The error bars were then included in the chart according 
to the standard error calculated. From the chart (Figure 3.13) we can observe 
that the error bars between 293T cells with and without IFN addition do not 
overlap, however, the distance between the bars is less than the length of each 
bar, which means that these measurements are statistically significant. Also, 
for all the cells transfected with viral genes, the error bars for cells with IFN 
added and the error bars for cells with no IFN addition overlap confirming 
that these results are also statistically relevant.  
The transfection efficiency was measured using the β-galactosidase 
assay system. In order to do this, the cells were also transfected with the 
plasmid containing the gene that codes for the protein β-gal and the 
absorbance at 420nm was measured. These measurements (data not shown) 
allow us to correct for any differences in transfection efficiency. 
We then attempted to generate a permanent cell line expressing this 
protein in the A549Luc cells. The A549Luc cells were infected using the 
lentiviral system previously described. From there, the new cell lines were 
subjected to an immunoblot to reveal the presence of the desired viral protein 
in the cells. In the Figure 3.14, we can see a band of 36kDa that corresponds to 
 Figure 3.13: Transient co-transfections in 293T cells with a vector 
containing the viral protein (Rabies P, PIV5V or MumpsEndersV) and the 
pISRE-luc reporter plasmid.  
 
293T cells set to grow in 75cm3 flasks, were co-transfected with the 
pISRE-luc reporter plasmid and with the plasmid reporter pdl’ PkIB where 
the viral gene was cloned. The cells were then stimulated by the addition of 
IFN. Figure 3.13 shows the average activity measurements for 3 assays on 
which the cells were incubated with and without IFN and measured for 
luciferase expression using a luminometer.  
We can observe that when IFN is added to the cells there is an increase 
in the amount of luciferase expressed. This increase is due to the up-
regulation of the ISG. However, the increase is less accentuated in the cells 
transfected with a viral gene, which suggests that in these cells the IFN 
signaling pathway is being affected by the viral protein. The represented error 
bars indicate that the difference between the amount of luciferase expression 








 Figure 3.14: Immunoblot analysis targeting the Rabies P protein using 
anti-Pk-tag antibody 
 
In order to check if the A549lucRabiesP cell lines expressed the viral 
protein the cells were set up in a 6-well plate and an immunoblotting assay 
was conducted using the anti-pk-tag antibody. Bands representing the protein 
for both Rabies strains are visible at 36kDa in this figure.  Two samples for 
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the molecular weight of the P protein suggesting that these cells are 
expressing Rabies P. After we obtained a stable cell line, we assayed the cells 
by measuring luciferase expression and checked the affects of the viral 
protein on its expression. If the viral protein down-regulates the expression 
luciferase, it means that the same viral protein is responsible for partially 
blocking the IFN signaling pathway, as explained. From the resulting chart 
(Figure 3.16) we can observe that (in the presence of IFN) there is, indeed, a 
reduction in the amount of luciferase expressed by the cells expressing the 
viral protein P when compared with cells not expressing the same protein. 
The expression of luciferase is, however, not the same for both strains of 
Rabies virus. In fact, we can observe that the amount of luciferase expression 
in the cells expressing the Rabies P SADL16 protein is, in the presence of IFN, 
higher than the amount of luciferase in cells expressing the Rabies P BH 
protein. A reasonable explanation for this result is that in cells expressing 
Rabies P SADL16 protein only the STAT1 nuclear import is being blocked, 
whereas in the cells expressing Rabies P BH the viral protein is most likely 
able to circumvent the IFN signaling pathway by interfering as well with 
other members of this pathway. Since only one measurement was taken for 
each sample, n=1 no standard error could be calculated. Therefore, these 
results can only be considered preliminary since the repetition of this assay is 
essential to draw any conclusions. 
An immunoblot targeting the protein STAT1 (Figure 3.15) shows that 
the band corresponding to STAT1 is slightly smaller and less intense for 
A549luc cells expressing the Rabies P protein when compared with those cells 
not expressing the Rabies P protein. Also, we can observe that the cells 
expressing the Rabies P SADL16 exhibit less STAT1 expression than the other 
strain of Rabies P protein. Once again, this result suggests that the target for 
the P protein in the SADL16 strain is only the protein STAT1 while, in the BH 
strain, the P protein may block IFN signaling by indirectly interfering with 
STAT1 expression.  
 
 
  Figure 3.15:  Immunoblot analysis targeting STAT1 protein in the 
A549LucRabiesPSADL 16 cells and A549LucRabiesP BH cells 
 
The A549LucRabiesPSADL 16 cells and the A549LucRabiesP BH cells 
were set up in 6-well plates and IFN was added to every other well 24 hours 
later. An immunoblot was then conducted in these cells. From Figure 3.15 we 
can observe that in the A549Luc cells expressing the Rabies P protein, and to 
which IFN was added, there is a band at 90kDa corresponding to the 
molecular weight of STAT1. This does not happen in the absence of IFN. 
However, in the cells expressing the P protein the band is not as intense as 
when compared with the same band in A549Luc cells. This tells us that in 
cells expressing the Rabies P protein there might be a partial blockage of the 
STAT1 protein and therefore of the IFN signaling pathway.  This result is 
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 Figure 3.16: Luciferase Reporter Assay conducted in A549LucRabiesP 
(SADL16 and BH) cell lines. 
 
A549 cell lines containing the luciferase reporter plasmid were infected 
with  lentiviral particles containing the RNA coding for the Rabies P protein 
and were grown in 75cm3 flasks. These cells were then stimulated by the 
addition of IFN 48 hours post-infection. After 8 hours a luciferase reporter 
assay was performed with these cells. As negative controls in the same assay, 
A549Luc cells were used. The obtained values were used to construct the 
following chart. In this chart we can observe that for A549Luc cells the 
expression of luciferase increases immensely when IFN is added to the cells. 
In the cells expressing the viral proteins there is also an increase in the 
amount of luciferase expressed. However, this increase is significantly lower 
than the one in the A549Luc cells. This result is especially noticeable in the 
A549luc RabiesPBH cells. This result indicates that in the A549Luc cells 
expressing the Rabies P protein there is a decrease in the ISG promoter 
expression. In turn, this suggests that the IFN signaling pathway is being 






























4.1. Engineering Cell Lines for Compound Screening Assays in 
Hep2Mx1TIPSE Cells 
 
In order to manufacture novel antiviral drugs, chemical compounds in 
high throughput screening assays are selected based upon their capability to 
block viral protein action in host cells. In order to be used in this kind of 
assay, reporter cell lines expressing certain viral proteins were engineered. 
The viral proteins (IFN antagonists) HCV core, HBV core and precore were 
reported to block the IFN signaling pathway by interfering with the 
Jak/STAT signaling cascade. As they block the pathway, these viral proteins 
interfere with the up-regulation of a significant number of genes that limit 
viral replication and proliferation. 
 The cell lines were generated using the previously characterized 
reporter cell line Hep2Mx1TIPSE, which contains the resistant genes TK and 
pac under the control of the inducible promoter Mx1. Mx1 is one of the 
antiviral proteins induced upon IFN production; its transcription is up-
regulated by the Jak/STAT pathway. 
 In order to generate the cell lines, the sequences coding for the viral 
proteins were cloned into a reporter plasmid, which had the selective marker 
blasticidin. Through a lentivirus based vector system, the Hep2Mx1TIPSE 
cells were infected with the lentivirus containing the RNA that codes for the 
viral proteins. Hep2Mx1TIPSEHBVcore and Hep2Mx1TIPSEHBVprecore cells 
were tested for viral protein expression using immunofluorescence whereas 
Hep2Mx1TIPSEHCVcore cells were tested using immunoblotting techniques. 
Several assays were also performed to the viral Hep2Mx1TIPSE cells to 
determine if these viral proteins were able to block the IFN signaling 
pathway. The first of such assays was an immunoblot targeting the protein 
STAT1. When the IFN signaling pathway is activated, this protein is 
phosphorylated and forms a heterodimer with STAT2. This heterodimer then 
translocates to the nucleus of the cell up-regulating different ISGs (including 
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the gene that codes for the same protein STAT1). The purpose of this assay 
was to show that in the presence of IFN, the amount of produced STAT1 
protein is diminished in the cells expressing viral proteins when compared 
with cells not expressing these proteins. However, the results stated the 
opposite: none of the viral proteins appeared to be blocking the IFN signaling 
pathway by interfering with STAT1 production and/or phosphorylation since 
the amount of this protein was the same for Hep2Mx1TIPSE cells and for the 
cells expressing the viral proteins (Figures 3.10 and 3.11). 
Another assay performed on the cells tested them for survival in the 
presence of the antibiotic puromycin (Figure 3.12). If the viral proteins were, 
in fact, blocking the IFN signaling pathway, then the ISG that codes for the 
protein Mx1 would not be up-regulated and, since the pac gene is under its 
control, the cells would become sensitive to puromycin. Therefore, in the 
presence of IFN the cells expressing viral protein should die while the 
Hep2MX1TIPSE cells survive the puromycin addition. By observing the plates 
in Figure 3.12c we notice that the cells expressing the viral protein HCV core 
survived the antibiotic addition, suggesting that in these cells the viral 
proteins are incapable of preventing the induction of the puromycin 
resistance gene. The cells expressing the HBV core protein (Figure 3.12b), 
however, died, suggesting that in these cells, the IFN signaling pathway is 
being affected by the viral protein and that the Mx1 protein production 
therefore is being impaired. For the HBV precore protein, the results were 
similar to those of the HCV protein suggesting that the extra 29 nucleotides 
that this protein contains in comparison with the HBV core protein might 
make a difference in its ability to interfere with the expression of Mx1 protein.  
There are, however, a number of considerations to be taken into 
account regarding the obtained results. The infections of Hep2Mx1TIPSE cells 
with the lentiviruses may not have been as successful as required. To have a 
maximum possibility of selecting a homogenous cell line where all the cells 
express the viral protein, the maximum number of cells should be infected 
with only one lentiviral particle. To ensure this happens, a sub-cloning 
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protocol may be employed on the cell lines. However, this procedure requires 
additional time not available for the completion of this report. 
Finally, when the Hep2Mx1TIPSE cells were set up in the 96-well 
plates in the absence and presence of IFN subjected to GCV addition, we 
received clear and expected results (Figure 3.1). However, when several 
attempts were made to use GCV in an identical assay in the cell lines 
expressing the viral proteins HBV core, HBV precore, and HCV core, the 
result was unexpected cell death for all cells with or without IFN. This may 
have occurred because we were unable to optimize the concentration of GCV 
or for other unknown reasons. 
 
 
4.2. Rabies P pdl’SurPkIB Transient Transfection 
 
In this study, we attempted to engineer a permanent cell line 
expressing the viral protein Rabies P in A459Luc reporter cells.  
But, initially, we transiently co-transfected 293T cells with the 
RabiesPSADL16PkIB or the RabiesPBHPkIB plasmid and a vector containing 
the luciferase gene under the control of an ISRE promoter and compared the 
activity of the promoter in these cells in the absence and presence of IFN by 
measuring the luciferase expression. As a negative control, we used 293T cells 
non-transfected with the vector expressing the viral protein. The two positive 
controls used were the viral proteins PIV5 and MumpsV. The genes coding 
these proteins were cloned into the same reporter vector as Rabies P. Both of 
these viral proteins are known to block the IFN pathways.   
 The aim of this assay was to discover if the ISRE promoter was being 
affected by the expression of the viral protein, indicating that this protein 
would be responsible for a blockage of the IFN signaling pathway. From the 
results, we conclude that there is a considerable down-regulation of the ISRE 
produced for both strains of Rabies when compared with the control cells (Fig 
3.13). This result supports the published data (Brzozka et al., 2006) indicating 
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that Rabies P protein is, in fact, responsible for a partial blockage of the IFN 
signaling pathway by interfering with the protein STAT1. 
By analysis of the error bars, we can confirm that the increase of 
luciferase expression when IFN is added to the cells is significant. However, 
we only performed 3 measurements for this experiment and an accurate 
statistical analysis requires a higher number of measurements. 
Because 293T are extremely sensitive, using them for luciferase 
reporter assays is a very delicate process. They attach weakly to surfaces and 
monolayers and can be disturbed easily by any compound introduction. 
However, alternative cell lines, which can be used for transient transfections 
like Hep2 cells or Vero cells, have very low transfection rates. 
 
4.3. A549Luc Rabies P reporter cell line 
 
With the intention of constructing a reporter cell line expressing the 
viral protein Rabies P, the gene P was cloned into the pdl’ SurPkIB reporter 
plasmid and, through the lentiviral-based system described above, the 
A549Luc cells were infected. The resulting reporter cells were tested 
according to their ability to block the IFN signaling pathway. This was done 
by measuring luciferase in the absence and presence of IFN and by comparing 
those values with the corresponding differences in A549Luc cells not 
expressing Rabies P. 
The results (Figure 3.16) show that although there is an increase in the 
amount of luciferase expressed in the presence of IFN compared to when it is 
absent, this increase is not as intense as it is for A549Luc cells. However, since 
there is an increase on the luciferase expression in the presence of the IFN, it 
means that the IFN signaling pathway is not being completely blocked. This 
may be because the level of P protein necessary for a complete blockage 
would be much higher than what is probably being expressed. The level of P 
protein expression is important since it appears that this protein does not 
interfere with STAT1 by degrading it, as other proteins do (PIV5V), but 
instead, it (Brzozka et al., 2006) impairs its nuclear uptake and therefore 
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higher concentrations of P protein might be needed. Furthermore, it might be 
necessary to impair other IFN signaling proteins to ensure a complete 
blockage of the IFN signaling pathway. In fact, we observed that the amount 
of luciferase expression in the cells expressing the Rabies P SADL16 protein 
was higher in the presence of IFN, than the amount of luciferase in cells 
expressing the Rabies P BH protein. We therefore assume that the P protein in 
the RabiesBH strain is able to interfere with other proteins of the IFN 
signaling pathway. It is known that the P protein in this strain of Rabies is 
able to impair IFN production by blocking TBK-1, essential for IRF3 induction 
(Brzozka et al., 2006).  In this particular project we were only testing the 
ability of the viral protein P in blocking the IFN signaling pathway. It would 
be, however, interesting to study the ability of this protein in impairing the 
IFN production pathway and compare it with the Rabies P SADL16 strain.  
As mentioned above, a number of repetitions of the luciferase assays 
need to be performed and the statistical significance of these results has to be 





Obviously, a major difficulty in this study was the generation of stable 
cell lines that had a good efficiency of viral protein expression. The 
construction of cell lines had two purposes: first, as a short-term goal, to 
detect whether or not the viral proteins in question were responsible for 
blocking STAT1 and therefore the IFN signaling pathway; second, in the long-
term, to obtain a stable cell line which could be used in compound screening 
assays (an essential step in the manufacturing of antiviral drugs).  
Regarding the first objective, we can only conclude that the viral 
proteins (HBV core and precore and HCV core) at their current level of 
expression in the cell lines are not able to block the STAT1. In order to 
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increase the expression of the proteins, an alternative may be used that 
involves adenoviruses.  
Adenoviruses are double-stranded DNA viruses. Recombinant 
adenoviruses are known to be extremely capable elements of gene delivery 
into mammalian cells. They can deliver genes into a huge selection of cell 
types including dividing and non-dividing cells, primary cells, or cell lines. In 
this alternative, a recombinant adenovirus vector is generated in order to 
express the protein in question. The recombinant adenovirus is then used to 
infect the Hep2Mx1TIPSE cells at a desired Moi (Multiplicity of infection).   
Next, an immunoblot and 96-well plate puromycin assays may be conducted 
in order to determine whether or not the viral proteins are blocking the IFN 
signaling pathway as expected. The adenoviruses are an extremely attractive 
vehicle of gene delivery because they can produce large amounts if highly 
purified recombinant virus (Wilson et al., 1996). Therefore, using recombinant 
adenoviruses could increase the expression of viral proteins to a level that 
would allow us to see the proteins blocking the IFN signaling pathway. Note 
that this procedure does not result in the generation of a stable cell line since 
the adenovirus infection is a transitory process. 
In the long-term, however, by using procedures such as sub-cloning 
(see 2.3.5), we may be able to produce successful, stable reporter cell lines that 




With the emergence and reemergence of viral infections, the processes 
with which to discover drugs capable of preventing or curing viral infections 
have enjoyed enormous developments in recent years. Screening assays to 
find chemical compounds that qualify as good antiviral drug candidates have 
been conducted. The aim of this project has been to develop cell lines 
expressing viral proteins capable of efficiently blocking the IFN signaling 
pathway that can be used as targets for those screening assays. In this project, 
A549LucRabiesP reporter cell lines were developed and can now be used to 
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screen compounds with antiviral potential. They have however, to be 
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